Podcasts about Gerstein

Stephanie Rupp (Hoffmann Eitle) and Ryan Phelan (Marshall Gerstein) explore how AI is reshaping medtech innovation and the IP strategies founders need to know. They break down key trends, from traditional model training to today's generative AI workflows, plus common pitfalls like novelty-destroying disclosures in pitch decks, websites, and investor conversations. Ryan explains why “file early” matters in the U.S. (and how provisional applications can backfire if they're too thin), while Stephanie shares how Europe's strict novelty rules and EPO “technical effect” requirements change how AI patents must be drafted. The conversation also covers cross-border collaboration, the Unified Patent Court, and why strong IP can become a startup's moat for investors and future growth. Guest links: https://www.marshallip.com | https://www.hoffmanneitle.com/ | rphelan@marshallip.com | srupp@hoffmanneitle.com  Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 089 - Stephanie Rupp & Ryan Phelan [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference.  Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I'm delighted to welcome as my guests Stephanie Rupp and Ryan Phelan. Stephanie's technical expertise stems from working in various fields of electrical engineering and information technology. She is particularly interested and experienced in communication technology, telecommunications engineering, and artificial intelligence due to her time at the university and various projects in the industry. For example, Stephanie gained industry experience with a leading technology company of measurement and high-frequency technology in the field of measurement technology for LTE. Working with a variety of clients from all over the world, Stephanie specializes in prosecution and oppositions at the European Patent Office and German Patent Office, freedom to operate, and patent drafting, in particular in the fields of computer-implemented inventions. Stephanie studied electrical engineering at the Technical University of Munich. She wrote her master thesis at the Chair of Communication Networks in the field of artificial intelligence with a focus on reinforcement learning. Ryan is a registered patent attorney who counsels and works with clients in all areas of intellectual property with a focus on patents. Clients enjoy Ryan's business-focused approach to IP. With an MBA from Northwestern's Kellogg School of Management, Ryan works with clients to achieve their business objectives, including developing and protecting their innovations and businesses with IP. Ryan has been published in several well-known IP publications, including World Intellectual Property Review, Bloomberg Law, and IP Litigator, and has spoken as a panelist at various IP conferences, including for the International Intellectual Property Law Association and for the University of Illinois Chicago Annual IP Conference. Since 2024, Ryan has been selected for inclusion in The Best Lawyers in America list in the practice of patent law. All right, Ryan and Stephanie, welcome to the show. I'm so glad that you are here. Ryan, this is your second time. Delighted to have you return, and Stephanie, I can't wait to learn more about you and all the ways that you both contribute to the industry. So thank you both so much for being here. [00:02:54] Ryan Phelan: Yeah, thank you. Yeah. Glad to be back. [00:02:56] Lindsey Dinneen: Awesome. [00:02:56] Stephanie Rupp: And thank you v- very much for having me. [00:02:58] Lindsey Dinneen: Yes, of course. Well, I would love, if you don't mind, starting off by sharing just a little bit about yourself, your background, and what led you to medtech. [00:03:09] Ryan Phelan: Yeah. So I'll kick it off. My name's Ryan Phelan. I'm a partner at Marshall Gerstein, which is an IP boutique here in Chicago. I have a computer science background, so I see the world through, you know, everything computers and, of course, nowadays that means AI. On the, the medtech side you know, I, I have, experience in robotics and so, a lot of medtech devices are in the robotics field, so it's very natural for me to apply my skill set, to that, area of expertise, one of which is, prosthetics. So you have a robotic, prosthetic medical device, and that lends itself to, you know, some type of computational control. And there's certain, legal issues that usually come up in, the US practice. So I enjoy, applying that skill set, to the, to medtech space. also, you know, family members als- have, you know, ailments and things that, I have, grown up with, you know, as a, you know, young boy and, now I'm very happy to you know, give back in my own way. I'm not a doctor. I'm just a-- I'm a, I'm a humble patent attorney, but, helping the, IP world, and, doctors and physicians, with not only, you know, in the robotic space, but also, software medical inventions as well, and I, enjoy working in this space. [00:04:22] Lindsey Dinneen: Love it. Thank you so much. Stephanie? [00:04:26] Stephanie Rupp: Yes. So as you hear from my accent, I'm from Germany, specifically from Munich, so that's a city in the southern part of Germany, close to the Alps. people might probably know Munich from the Oktoberfest that we have each year. And, so I'm a German and European patent attorney at Hoffmann Etile. I also throw it in as well, I'm also UPC representative, so we have, for three years now, we have the Unified Patent Court, so a really new court in Europe for centralized litigation for infringement and revocation actions. So I can also represent clients there. yeah, Hoffmann Etile is a, also a p- a IP boutique firm. not only in Germany, we also have offices, in other places in, Europe. And, yeah, my technical background is electrical engineering and information technology. And, during my studies, I just didn't work a lot in the medtech space. I was, ... my work concentrated more on the telecommunications side, working in a, bigger f- company that, concentrated on measurement and high-frequency technology. But, my master thesis was already about AI, so it was at the Chair of Communication Networks, and it was about, like, reinforcement learning, virtual network embedding. I won't say too much about that. I think it will bore the listeners. But so I didn't know at that time, but it opened my way to the medtech space afterwards. because when I joined Hoffmann Etile nine years ago with my training, the partners were really happy to hear that I have experience in the AI field and the technical background on that. And, around nine years ago, we saw a lot of patent applications being filed in the AI space, like using AI technology in different technical fields, and especially also in the medtech, field. And, so I had the opportunity to jump in there, like, right away when I started and was really happy to do that and also, like, still very glad to have that opportunity to work with the medtech, companies and to get the best patents for them in that, especially in that field. [00:06:26] Lindsey Dinneen: Awesome. Thank you so much. Yeah, thank you both. So, all right. I have so many questions, but I will start here. I'll just, 'cause I'm curious. So how, how did you two meet? Do the firms come together and, and, collaborate? [00:06:38] Ryan Phelan: Yeah, absolutely. so Marshall, Gerstein and Hoffmann, Eitel had a relationship prior with, attorneys, that go back a generation or two, before Stephanie and I met. And so, their-- one firm would send attorneys to the other and vice versa. And then, after a while, given that Stephanie and I have similar backgrounds, it was very, simple just to connect us. And then we've worked together on matters, before and have similar backgrounds like Stephanie mentioned. She has electrical background, but has done a lot of stuff with AI. And so whenever you're doing, matters across the pond, as they say, you need expertise, in the EPO and the US and the laws are different, so you have to collaborate. And it's great to have, have people that you can collaborate and work with. [00:07:21] Stephanie Rupp: Yeah, and a lot of clients, they're not only interested in getting an EP patent, but they also want to get a US patent. And, I'm not a US patent attorney, so, usually tell them, "Oh, yeah, I know a really good patent attorney in the US." And, thank you ... so I will, like, hand over the work to him and then the other way around if they have, like, clients that they want to get a EP patent, and that's how we work together and, also dis-discuss these cases together. And, so yeah, I'm currently in Chicago for a week, also to meet Ryan in person again. I do that, usually once a year. And, yeah, just have time to discuss some cases more regularly. [00:07:55] Lindsey Dinneen: I love that. That's cool. [00:07:56] Ryan Phelan: Yeah, I was in, And I was in beautiful Munich last year, so it was, it was great. [00:08:00] Lindsey Dinneen: Very nice. That's wonderful. Okay. So again, so many things to talk about, but I, I, I'm curious in your interpretation of how AI has affected, especially the legal components of, say, filing a patent or IP protection or all of those things. When it comes to medtech founders, what are you seeing the trends to be, and also, what are some of the pitfalls to avoid? [00:08:29] Ryan Phelan: Yeah. So I've seen AI affect everything from filing strategy or information, gathering, like on the pre-stage of a patent, and then also, the invention itself, has also included AI. I think about it as like AI 1.0 and 2.0. before, 1.0 AI is, a lot of software inventions would train their own models with their own data. Maybe you have a, a cardio, application or something like that, that would use existing, information from patients and, that information, would be used to train a model, and that model would be able to output some type of response for a future patient. Maybe that model was inside of a device that was, implanted or, put on top of, a patient where that sensor data would be collected.  Nowadays, in, in tho-those inventions, usually incorporated some type of trained model. Nowadays, you have a lot of generative AI, where newer inventions are using out-of-the-box models from OpenAI, ChatGPT models, or Anthropic's Claude models. And, a lot of the same issues are still being addressed, where data will, will come from various sources, whether it's a patient's data or clinician's, or maybe it's, a diagnostics or maybe it is more in the robotic space for, prosthetics. But that data is now, instead of being pushed into more traditional models that would be trained, is now being used by these generative, LLMs. And then you can have combinations of the two. So it's, become an explosive field in AI at least from what I have seen. People are getting excited that you have these large treasure troves of data that you can synthesize, the information inside of it and then get some type of, useful output, and then you also have inventors that are seeking solutions, asking, LLMs to help find a particular solution, and they'll add to it. And our invention disclosures that we get, I, I typically joke and say, "Used to, it was hard to get an invention disclosure from an inventor." They would send you, like, a paragraph or two of the invention, and you'd be, "Well, is there anything else?" And now it's, they'll send you 100 pages of stuff. And like, "Well, let's, well, let's talk about what's relevant. Let's find the needle in the haystack here." So AI is, is influencing all sides of the invention from when it's coming in the door and then how, how, what the invention makeup is itself and how that's gonna be protected in the future. I, I see a lot-- In, in the future, I, I can predict or hopefully predict, there's gonna be, a lot of litigation or a lot of, like, questions about who owned what in the future for patents. So that's, that'll be interesting to see, too. [00:11:06] Lindsey Dinneen: Yeah. Absolutely. [00:11:07] Stephanie Rupp: Yeah- I think what I just want to add is, that it also changes how we work. I think in the past it was, so we had, like, these different departments. We had mechanics, e-tech, biotech, chemistry, and it was, like, very clear when you get a new patent, like an invention disclosure in which department you will push it and, like, who will work on that. But now we have, like, more these interdisciplinary inventions especially, like, in medtech, pharmaceutical companies that are using AI and, and that also changes how we work, that we are trying to then find a interdisciplinary team as well, having, like, patent attorneys from different technical backgrounds, because I'm looking at a invention disclosure differently than a patent attorney with a chemistry background. And, so that makes very interesting for us as well, 'cause we have to work together and, that's why sometime I get a call from the biotech department saying, "Oh, we have a invention disclosure with a lot of AI in there. Could you maybe help us out?" And, so that, yeah, it, like, changes our way of working in there as well. That makes it very interesting. [00:12:12] Lindsey Dinneen: Yeah. That's very interesting, and I actually love that. It seems like a lot of, ability to learn from each other in that way, and so yeah, I love that exposure. So, okay, when it comes to filing patents, and protecting your IP in general, I'm, I'm curious what your advice is for, for founders that maybe have, like, basically timeline, when should they be thinking about engaging with you all, and h- how do they go about that? Just what is, especially for these younger startup founders, what's some advice that you just, you go, "Okay, now's the time. Here's what we need," and, and whatnot? [00:12:51] Ryan Phelan: Yeah, I always advise as early as possible. Okay. usually it's-- usually most founders or startups are not thinking about patents in the beginning. But, you know, I always like to, to tell them when, when I'm speaking to a founder of a startup, think about it as insurance or similar to insurance, because at the end of the day, if you become very successful with your, medtech product, whatever it may be, people are gonna wanna copy you. [00:13:13] Lindsey Dinneen: Yeah. [00:13:13] Ryan Phelan: And, that, that's probably not only important to you, but also to your investors, if you have them. If, like, you're seeking money from others, whether it be seed money, angel money, or series A, series B the, these people are probably gonna ask you what's your moat, what's your, what's your barrier to entry for others, so if your product, takes off, because they're thinking in terms of, "How much money will I get back if I invest?" It's gonna be s- 20x. And so, it-- they know, and the startup founders should also be aware that if somebody else comes into the market, especially a big player, and they, replicate your product or your software, then that could take market share from you. And so having a patent or building that patent portfolio at the same time, it protects you, from that. It also, of course, there's times, timing, that you have to be mindful of. As soon as you disclose something in the US, it kicks off a, a one-year clock... [00:14:04] Lindsey Dinneen: Hmm ... [00:14:04] Ryan Phelan: ...for you to file something. Just to get an invention in the US, and Stephanie, can let you know about, you know, elsewhere- Mm-hmm ... and in the EU, I understand that there's an absolute bar. Yeah. But for that reasons, for that timing purpose of when someone discloses your invention, and that can be a part of a pitch deck to a set of in- investors, if you don't have a non-disclosure a- agreement, an NDA, then that could also start that clock ticking. So you wanna be mindful. Do this in parallel at the same time, seeking to get your, patent, at least a provisional patent, on file before you go forward. [00:14:37] Stephanie Rupp: Okay. Yeah, as Ryan said, at the, in Europe, we don't have this kind of this year to file a application. Once you publish something, then it's out on, out there in the world and, endangers your own patent application. Because if you want to get a patent the claimed subject matter needs to be novel and inventive. And if you have, like, published this before, then that's prior art with respect to your own patent application. So you always have to keep that in mind and, that's why it's so important to file the patent application first before you use that information for advertisement, for example. And I, we see that often, with startups, and I complete- completely understand. They're super excited with regard to their, like, great idea, and they want to shout it out to the world. But once it's out there that hinders you to get a patent. so- As Ryan said, it's good to think about patents from the beginning and also, the market you're interested in, maybe about competitors and where they're in, which countries they're involved, and then you could also think about, okay, maybe, that is a market of your interest, and then also get advice from patent attorneys in that country because it's different from which d- like, from jurisdiction to jurisdiction how to get a patent, and you want to get the broadest patent as possible. And, especially with AI inventions, where they're the requirements are so different in the different countries, it's, good to have the advice from the beginning on so the patent application is written in the right way. Because once the patent application is filed, we cannot add anything anymore, or we cannot change it. That's why it's, like, good to have really a, like, a well-written patent application also for the jurisdiction you want to go in. [00:16:25] Lindsey Dinneen: Okay. Yeah. Thank you both. That was really insightful. I'm, I'm curious about the patent application itself. Is there-- Well, two questions, I suppose. Is there also a kind of provisional patent opportunity outside of the US, just out of curiosity, as, as well as in the US? And then also, you know, you mentioned being very careful and cognizant about the way that it is written, which of course now you two being experts in this, you know, back, you know, like the back of your hand. But I wonder, if people try to do it themselves. I would love just to hear some advice about that as well. [00:17:06] Ryan Phelan: Yes. Stephanie, do you wanna talk about the provisional outside the US and- [00:17:09] Stephanie Rupp: Yeah. So in Europe, we don't have that provisional applications or non-provisional applications. what you have though is the priority year. So you can, like file an application, for example, first in Europe, and then you have a year to decide which other countries you want to go to, and then claim priority from that European patent application. So, I file a EP application, then after a year I think, okay, I want to go in other countries, I want to maybe file it, one in the US, then you can claim the priority from there. And the previous patent application that you filed will not endanger the other patent application. So that's one way of doing it, to buying yourself a little bit of time. Also, sometimes clients when they're like very cost sensitive, especially for startups, would first think, okay, we file a patent application first to Europe, and you get a, a search report within the priority year from the EPO. And then you already know the prior art that is out there, and you can assess how strong your patent application is, and then you can still decide, how to proceed from there. So there are like some ways of how you could do that. [00:18:19] Lindsey Dinneen: Awesome. Thank you. [00:18:22] Ryan Phelan: Yeah. In the US, of course, we have provisional applications. It, it causes a great, amount of confusion, though, the provisional applications. A lot of startup companies will think that they can file a provisional application and it'll be, you know, a page or two in length, and then they can wait a year and inflate that to 20 pages or, or something like this. And of course, the, the trap for the unwary is, of course, if the claims, when you draft those for the non-provisional or the conversion application, if they are not grounded in that first provisional application, if one element of one of the independent claims, for example, is, s- solely supported by the new material added in the, the new, you know, 20 pages or whatever it may be, then the support gets you the date of your non-provisional conversion filing and not of the provisional. So, usually for startup clients, I have to-- we ta- we have this conversation called the delta. What's the delta between your provisional and your non-provisional? If there's a lot of it, then, that could be a problem because if your claims aren't supported by the text of that provisional application, you're not gonna get that original date. And so, usually that kicks off a conversation of how much of a provisional that you want, or do you just wanna go all non-provisional. Now, I do litigation as well, and I can tell you, the, the, the pitfall is if you file that provisional and you file a non-provisional later and you end up getting that later date, if there is intervening prior art in between, the provisional date and the non-provisional date, that comes before your non-provisional date, that could invalidate your patent despite your provisional. And there's, parties debate this. They, excuse me, fight about this in court all the time. Now, did you have sufficient written description and enablement in your provisional application in order to substantiate your claims later? And if they can find intervening prior art between that year or whatever the time may be, that can be a real problem. So, I, I always c- I always tell clients, like, the, the more you can file up front, the better, because you're gonna get more support or more, possibility to have that support earlier in time. Of course, it takes more work. Most startups don't like to hear that, but it is, but it is the truth, and it does, it does protect them against that insurance policy. You, you add it up front. Like Stephanie said, you wanna, put that information, on file before you go out and do your advertising and marketing. That's also true in the US. Just filing a provisional application, does not in and of itself somehow protect you if, if you don't, if you don't say what it is that you're trying to protect. [00:20:48] Lindsey Dinneen: Yeah. Okay. That makes a lot of sense, and thank you so much for that insight. So you mentioned a couple of times that sort of disclosure component, and so just to d- just be very specific about that whole thing you mentioned that could be-- that could look like even just a, a pitch deck where you think it's potentially within a, a private setting thing. Of course, I would imagine that also extends to talking about it on social media or a website or something like that. So I'm just curious what are some of the things that you see besides maybe perhaps the broader, more obvious, like a website, what are some of those things that you see that people don't think to, be aware of, I guess? [00:21:34] Ryan Phelan: Yeah. I've seen websites. It's super easy to create a website nowadays. You can ask ChatGPT or Claude to generate a website, and if you're putting your invention out in a website form before you file a patent, that could be a novelty-destroying disclosure. if you have a detailed pitch deck that you give to, potential investors without some type of control, like an NDA, that could also be a novelty form of disclosure. Like in the US, for litigation, I, I can tell you one of the questions that always gets asked in discovery is, "Did you disclose this prior to the, the filing date?" And, if that person, that person will be required to answer under oath, and if they're, "Yes, I had a website," or, "I, I gave this pitch deck to 50 people for investing," usually that's a problem because that--the opposing side that's defending against that patent will do a, a deep analysis and, and look-- and try to find when that was disclosed, and does it map up to the claims, and that could, create a problem with, validity in the US. [00:22:31] Lindsey Dinneen: Oof. That's no fun. That's why they should talk- Yeah ... to you early and often. [00:22:37] Ryan Phelan: Yeah. Yes. Again, another example of filing early, you know, eliminates some of those issues. i-in fact, I tell a lot of the startup companies or any, any client, like, before you go out there and, you know, have your conference or your, your pitch, then file. Most sophisticated clients know this, but a lot of times startups do not. [00:22:54] Lindsey Dinneen: Sure. Yeah, and if you're a first-time founder or something like that, you wouldn't-- you don't know what you don't know for many different categories, so I can see why that is so critical. Yeah. Okay. So, I was wondering if both of you could talk a little bit about maybe, maybe a moment that has stood out to you as, as you've worked, especially with-within medtech and, and working with some of these founders. Are there any moments that really stand out as just affirming that, "Wow, I, I am doing the right thing in the right industry at the right time"? [00:23:28] Stephanie Rupp: Shall I start? Yeah. yes, I, I've-- So for me it was, like, never the plan to become a patent attorney and, and, like, never had that in mind. And, so it was more of a coincidence that I stumbled upon that and did the training and became a patent attorney and... But I still remember my first day in the office and having the feeling of, "Yes, I think that's what I want to do for the rest of my life." Like, continue learning, like, having, like, this incredible opportunity to speak with so many great inventors. Having, like, I don't know, it's always amazing, to see how their mind works and that they're, like, finding solutions for s- like, very complex problems. And, so that, like, from the day, first day on, I had, like, the feeling, okay, I think I can really help here and, protect their asset the best way possible. And then especially within the medtech field, I think what Ryan also said in the beginning, there's like, it's also for me, sometimes it's a kind of s- scary part thinking about, okay, what if you get sick at one point, or like from closer family that got really sick, and, having like this helpless feeling like that you maybe can't change anything here. And then when you work with the medtech industry and you see that they are working on that problem and have these great idea- to help people to like, that there's also k- some kind of involvem- like involvement in this technology. And, so for example, I, there's like one of my clients, they are, working on histological images and analyzing them also with respect to cancer types, and how AI can be such a great help there. And of course, there are like a lot of these discussions about, how we should be careful with the new technology and how we could re- regulate that and stuff like that, but there's also like so much good in there that can really help people's lives. And I think that's like for me, always very nice that yes, Ryan said we're no doctors. So like, we're just like patent attorneys, but still we could contribute a little bit to that too. Yeah. [00:25:34] Lindsey Dinneen: Love it. [00:25:35] Ryan Phelan: Yeah. I would just, I would just echo everything that Stephanie said. That certainly is why I enjoy working in this space too, is, you, you feel like you have a, a little bit of contribution that you make. [00:25:44] Lindsey Dinneen: Yeah. Absolutely. I, I couldn't agree more. I think, to your point, Stephanie, it's, it's so inspiring to see the innovation that's coming out, and it makes you feel like, especially when there's difficult world news, it makes you think, "Okay, but at least there are still these change makers who are really trying to make the world a better place and, and improve patient lives." And I think that's just a, a wonderful thing to get to witness and be a, a part of. It helps the soul. So, I'm always curious about the personal side of things as well. So just what are, what are some of the things that you all en- enjoy doing, say, outside of work? maybe some hobbies or volunteering or interests and things like that. What are... Let's, let's talk about the people as well behind these amazing patent attorneys. [00:26:36] Ryan Phelan: Yeah. everybody has a hobby, so I, I was, I like to run. I was running since high school, so I like to do that. And then, in the winter I like to ski. and then I'm, recently getting my scuba cert, with my daughter. So we're having a good time doing that this summer. So just trying to stay busy and active. I like to learn always, and so I, I, I love learning, I guess. and one of the reason why medtech is interesting to me 'cause I like to apply that, computer science skill to, the medtech field and continuously learn, in that space and also give back, like we talked about before. So, yeah, I guess I would lump in learning as one of my hobbies as well. I like... I, I'll say, and I, I'm not sure if we'll get into this later I think you had a question about, poss- if we, if we could teach one class or- No, we'll get into that ... [00:27:20] Lindsey Dinneen: Something like that. Yeah. [00:27:22] Ryan Phelan: Yeah, okay. I'll, I'll save that for a later time. So. [00:27:23] Lindsey Dinneen: Okay. Yes. Excellent. Stephanie? [00:27:28] Stephanie Rupp: Yeah, I think that's, one common thing that we have, Ryan and I. It's, skiing. That's also what I enjoy a lot. so as I said, I'm from Munich, and it's very close to the Alps, so it takes us only, like, about, like, two hours to go to Austria. and so, but I really enjoy going there for the weekend, clearing my mind. Yeah, especially when the week was very busy with work. so it's like, thinking about something else. And, besides that, yeah, spending time outside, going hiking at the weekend, like when it's... there's no snow. Also, I picked up some hobbies that I had when I was younger. So for example, I had, piano classes for, like, when I was five years old, and then once I had, like, the training and everything else going on, paused that because, like, so much else going on. But then last few years I, taught myself, "Oh yeah, it would be such a waste not to do that anymore." And, so I'm, like, started playing piano again. I'm not good in it. It's more really as a hobby. And, but yeah doing something else in the evening and clearing my mind. So that's what I usually like to do as well. [00:28:35] Lindsey Dinneen: I love that. That's wonderful. I, yes, I, I understand that sometimes picking up a hobby that you sort of set aside for a while is really fun as an adult, 'cause you have a different way of interpreting that learning, back to your point, Ryan, of how it, it it changes. And I, I actually really enjoy that, of, of revisiting something where I might have thought g- especially growing up. Like for instance, I remember thinking I just could not paint for the life of me, like it was never gonna happen. And then as an adult, with a, an instructor who was... maybe s- spoke a slightly different, in a different way, and then getting to like go, "Oh, maybe I can" is always a nice thing to learn too. But anyway. [00:29:17] Stephanie Rupp: And also taking, taking the pressure out of it. Yes. So it's like, as I said, like piano class is just a hobby. I don't have to be good in it. It's just should give me some joy in it. And so yeah. [00:29:27] Lindsey Dinneen: Love that. Yeah. Yeah, okay. So now you've both been in positions of leadership, and I'm curious, and, and I know it's hard to boil it down to maybe one thing, but what is one or two, three things that you would say is your top leadership advice, especially for those who maybe are more in, middle management trying to continue to build their leadership skills? And what, what makes a good leader, in your mind, and then maybe what's one or two pieces of advice? [00:30:02] Ryan Phelan: Yeah. What makes a good leader in my mind is something that somebody that can lead by example, I guess. On like a first project or a new client or a new matter, I like to do it, do it myself once so I can go through it and, get the feeling for the new technology, that may be at play or the new matter, maybe the client's preferences whether it's a startup or a large company. And then once I have that kind of lead from the front, then I like to do, I guess, a military word, dis- decentralized command, which is get people that I trust and who I have a great assistant. I have attorneys that I work with European attorneys such as Stephanie, and then give them work with them and give them free reign and control, whether it's a colleague like Stephanie or a associate here at Marshall Gerstein to, work with the client or have agency over, what they do, 'cause I think it can also teach in that capacity, like things that I learned from the lead from the front can flow, down or through or out and then, that person can also learn on the job doing it themselves. I believe that, people doing, instead of just listening is the, a best way to learn for them and then also get better. And so I, I tend to approach, leadership, from that perspective. [00:31:12] Lindsey Dinneen: Love that. Yeah. Stephanie? [00:31:15] Stephanie Rupp: Yes. I see myself like still more at the beginning of my career, so I can, talk a little bit more of how I, see or like, yeah, see leadership or like, how I experience it. Yeah. it's more also I... like everything what Ryan said, I completely agree. And also like seeing the person behind that. It's like everyone is like very busy, especially when you're in leadership positions and, very busy schedules and, But also seeing the person as a whole- Mm ... and how could you like support them to be better, to grow and, how to also, yeah- lead them or like, yeah, lead them in the way they w- where they want to be at some point. And, I think that's, yeah, what you should not forget e- especially when you have a really busy schedule. That's it. [00:32:11] Lindsey Dinneen: Yeah. The, the person behind... Yeah. That, that's an interesting theme that continues to come up, time and time again, is, you know, if one of the tricks to being a good leader is to care. It seems so straightforward, but it's if you care about the person and you, you want the best for them, you are going to naturally be a better leader because you're investing in them and, and in their success and goals, and, it's, it's just cool to see. Okay, and then, all right, I'm just going to pivot the conversation a little bit for fun, and this is where exactly what you were referring to earlier, Ryan. So if you were to be offered a million dollars to teach a master class on anything you want, could be in your industry, but doesn't have to be, what would you choose to teach? [00:32:58] Ryan Phelan: I would teach a class called Patenting Software Inventions and, I'm actually currently teaching that class. Oh. they're not-- I'm not getting paid a million dollars to do it, unfortunately. [00:33:07] Lindsey Dinneen: Dang. [00:33:07] Ryan Phelan: But, but it is a, a, a passion and a love. I teach it at, Northwestern Law, where I went to law school. I-- it's, it's my pleasure and joy every year to go back. I teach a power course there every year, I think for the past eight years on, teaching students how to patent software inventions in the US, and I think, elsewhere there's a, you know, there has become, by at least some people, the belief that you can't patent software, you know, which of course is, not true. And so, you know, I teach methodologies in my class about how to, patent software inventions in the US using you know, guidance from the courts, from the Supreme Court, from the Federal Circuit, from the district courts here, in the US. A lot of it covers, things such as Section 101 you know, that changed, in 2014, from the Supreme Court's decision in Alice v. CLS, and how to address, issues, about what the, the court said there. And then also what later courts, the Federal Circuit, said that they wanted to see in order to overcome, Section 101 issues, in the US. A lot of times, too, it's interesting, we have, like, a small slide like that, that deals with EPO-- which Stephanie's much more adept than, than I am-- but what we tell our students is, and maybe Stephanie can address this, is that, you know, there seems to be a convergence, between Section 101 law and, something called a technical effect, an EPO, where it seems like both jurisdictions are wanting to see more of a technical disclosure incorporated into the application rather than just kind of claiming functionally or a high level language. So you need to be very careful in crafting these applications so there's-- they're successful when you're in front of the the patent office in the US. And if you, you do it right, you can, create, you know, not only a US-centric application, but one that might, withstand, the strictures of the EPO. In my opinion, I think that the EPO can sometimes-- and maybe this is just me being a US practitioner-- but the EPO can be somewhat more difficult, to get a patent, application. Maybe Stephanie would disagree and say it's the other way around, but but it's always good, and clients usually, even if they're not thinking about it, to have an application that could survive both places 'cause they tend to be, I think, the, the two more, more difficult, if not most difficult jurisdictions in the world to get a patent application. And if you go into it knowing and how to craft a patent application and you're ready, and you put into that application the right, material, then you can be successful. [00:35:40] Lindsey Dinneen: Awesome. Stephanie, what would you teach? [00:35:44] Stephanie Rupp: Yeah, maybe we, Ryan and I, could do a master class together then because he said, like, then we could explain the similarities or the differences between, US patent law and European patent law, and can also maybe, also add something about the UPC that we have now, the U- Unified Patent Court, and have a, maybe a lively discussion about all of that and, how to get the strongest and broadest, patent in the different jurisdictions. And as Ryan said, there are, like, some similarities, and I also have the feeling when I discuss with Ryan that, when we have a patent application where we struggle to get a patent on, then we usually also struggle with that in the US- Mm-hmm ... or the other way around. And, but of course, there are, like, differences in how the EPO and how the USPTO, like examine these AI inventions and, in the US you have these 101 objections that you usually get. In, Europe it's, they apply the so-called two hurdle approach where they, especially the second hurdle is usually harder to overcome. Mm. And that's also what, Ryan mentioned, is that you have to show the EPO that your AI invention or your AI steps contribute to the technical character of the invention. And that's, often, and I totally understand that, hard to grasp for an inventor because they think we have all these technical means here. We have a server, we have a processor, we have a memory, we have sensors getting data. Do you tell me now that that's not technical? [00:37:18] Lindsey Dinneen: Mm. [00:37:19] Stephanie Rupp: And, but that's not how the EPO thinks. It's, for them, they say, "What is your motivation for that invention?" Or, or in other, more their words, "What kind of technical problem you try to solve?" [00:37:32] Lindsey Dinneen: Mm. [00:37:34] Stephanie Rupp: And that is, what we also usually ask the inventors in our f- like, first meetings with them, "What is the technical problem you're trying to solve with that, and how does the, your AI steps, your method steps contribute to that?" Because that's, if you cannot show that to the EPO, then it's very hard to get a patent on. so maybe my combined master class- yeah ... where we show that and- It, [00:37:59] Ryan Phelan: It would- ... [00:38:00] Stephanie Rupp: Explain that, yeah. So ... [00:38:01] Ryan Phelan: Definitely it would, it would help out my meager EPO slide, any additional information on this, especially the, the UPC, which I'm glad you mentioned. But, maybe, we could take a minute to talk about the UPC and in, in the European area since that's like a new, newer, from what I understand, a newer avenue, the era approach in Europe. [00:38:20] Stephanie Rupp: Yeah. Yeah. It's, so as I said, we have, like, for now three years now, the, Unified Patent Court. And, before that we also had European patents, but once it was granted, was divided into national patents. So if you wanted to, file an infringement action or a nullity action, you had to do that in each specific country. And that made it very complicated because I, I'm a German patent attorney. I don't know anything about Italian law, so you would then need an Italian patent attorney or French and so on. So it was, like, very complicated. And, so what we now have, and that is, like, very exciting to live at that time now, is, the Unified Patent Court, where it's, like, now centralized and you can attack patents at the, like, Unified Patent Court, like, for the whole patent, and you don't have to go to these before the national courts anymore. And, so that's, like, very exciting for us as well because case law is evolving now and, there's, yeah, you can see how, like, how it changes and how the judges are handling these cases and it's, like, also very, like, for us, a lot of new things to learn. [00:39:32] Lindsey Dinneen: Yeah. [00:39:32] Stephanie Rupp: Yeah. [00:39:33] Ryan Phelan: Yeah, I was gonna say, I, I also heard, and, Stephanie can certainly chime on this, that certain cities in Europe, like Paris, or Munich, may have different judges that specialize in different arts or disciplines. I think, was it, w- what Munich was, I can't remember, is that the mechanical or- Yeah. [00:39:49] Stephanie Rupp: Yeah. So that's, like, for the central division, but we also have then local divisions- Mm-hmm ... as well. So we have, four local divisions in Germany, but also in other countries. And that also, changes, of course, a little bit of how they handle the cases because the judges, they often came from the, like, the national courts. So they, like, when you're in Germany, of course, they still have little bit, little bit more of the German thinking in them. When you're going to a Dutch, local division, then they have a little bit of, like, another, like, view on that. And I think over time it will, like, unify a little bit. but these are, like, also differences that, makes it very interesting, to see. [00:40:27] Lindsey Dinneen: All right. Okay, so next question is, how do you wish to be remembered after you leave this world? [00:40:35] Ryan Phelan: I hope that people remember me as, somebody that was fun, like to, you know, either work or hang out with that regardless of whether we're working hard or, you know, playing hard, that, that it was just fun. So that, that's my only wish. So or, or main wish. [00:40:50] Lindsey Dinneen: Love it. Steph? [00:40:52] Stephanie Rupp: Yeah, I think for me that I was maybe, like, a fair and trustworthy person. I think it sounds a little bit boring, but, more when people work with me and they, like, say, "Oh, when she gave me advice, I knew that she had, like, my best interest in mind as well, and not only, like, filling her own pockets or, like, trying to, like, improve it for herself, but having like..." Yeah, when they remember me of a person that you could trust with the advice, I think that would be, like nice to know for me. Yeah. [00:41:26] Lindsey Dinneen: Yeah, for sure. All right. Excellent. And then final question. What is one thing that makes you smile every time you see or think about it? [00:41:37] Ryan Phelan: I guess just sticking with our current theme, if in a work capacity, when a client gets a victory of some type certainly makes me smile. A lot of clients are happy when they get their patents allowed, or if you win that litigation case or you, you do things, a lot of times in the US we'll, we'll have these decisions or these patents, and it it, it, it makes me smile to think that, you know, I helped their business in that way to protect their, their IP and just going forward. I, I imagine it's a pretty standard answer, but, you know, certainly in the context of this podcast, that's absolutely one thing that makes me happy. [00:42:10] Stephanie Rupp: Mm. Yeah. I'm a person, I get excited very quickly or, like, really small things make me smile already. So I arrived on Saturday in Chicago, and I, for example, didn't expect to have a gym in the hotel, and then suddenly I discovered that and was really happy about that. So these are these small things that other people say, "Oh, yeah, whatever." but I think what makes me smile the most is, like, knowing that I have a weekend ahead of me with, like, my family and my partner, and we go ski. And I say that now we have, like, summer outs and, like, very warm temperature here in Chicago. I think it's about 80 degrees, and I'm already thinking about skiing and snow, but it's, more of... [00:42:52] Ryan Phelan: It's never too early. [00:42:53] Stephanie Rupp: Yeah. But more of, like, not the skiing per se, but just having time with family and- yeah ... clearing my mind and stuff like that. So, yeah. [00:43:02] Lindsey Dinneen: Excellent. Excellent. Well, thank you both so much for being here. I've so enjoyed the conversation, and you gave so much amazing advice and guidance, so thank you so very, very much for all of that. If folks who should be looking out for services such as yourselves, how do they get in touch with you? [00:43:25] Stephanie Rupp: I think like through the website, that, I think will be- mm-hmm published, with the, podcast. And, also my email address as well. You can find me on the website, or we can also add it to the, to the podcast info. yeah. [00:43:38] Ryan Phelan: What is your... [00:43:38] Stephanie Rupp: It's the easiest ... [00:43:38] Ryan Phelan: What is your email address, Stephanie? [00:43:41] Stephanie Rupp: It... Hopefully I say it correct now. It's, S for Stephanie, S Rupp, my, last name, @hoffmanneitle.com, so very easy. Yeah. [00:43:53] Ryan Phelan: Perfect. Excellent. Yeah, same thing for me. I believe the contact information will be at the with the podcast, but I can be reached at RPhelan R-P-H-E-L-A-N @marshallip.com, and welcome any questions or comments. [00:44:08] Lindsey Dinneen: Awesome. Well, thank you both so much again for your time today. We really appreciate it. We are so honored to be making a donation on your behalf as a thank you for your time today to Save the Children, which works to end the cycle of poverty by ensuring communities have the resources to provide children with a healthy, educational, and safe environment. So thank you so much for choosing that charity to support, and also thank you for continuing to work to change lives for a better world. Love learning about you, about your areas of expertise, and just really appreciate you, being willing to share with us. So thanks again, and, I suppose until next time. [00:44:51] Ryan Phelan: Thank you. Love to come back. [00:44:53] Stephanie Rupp: Thank you. Awesome. Yeah. Thank you so much. [00:44:55] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

Lateral hiring is currently at an all time high and the cost of getting it wrong runs into the billions, so why are firms still making critical hiring decisions without using the right tools to get it right. This week on CMO Series: Lateral and Mergers, we are pleased to share this brand new episode. Eugene McCormick is joined by Mark Levin, Chief Marketing and Business Development Officer at Marshall Gerstein, Chicago's largest IP boutique firm. Mark has spent his career studying what makes legal talent succeed or fail, and led him to run a psychometric assessment company working with NFL Combine teams and AmLaw 250 firms. Mark shares his journey into talent assessment and development, what the legal profession still gets wrong about lateral hiring, and why IP attorneys present a unique challenge for any BD leader. Mark and Eugene dive into: His journey from law into psychometric assessment, and what the NFL Combine taught him about predicting talent What the legal profession still gets wrong about lateral hiring Why the true cost of a bad lateral hire runs so much deeper than the recruiting fee Why IP attorneys present a unique challenge for any BD leader What it actually takes to build a business development culture that sticks The tools firms need, but rarely use, when making high stakes hiring decisions

In this episode of Here I Am, host Shai Davidai sits down with Jewish advocate, organizer, and "campus mom" Valerie Gerstein, who shares her firsthand experience confronting antisemitism as a graduate student at Columbia University. Valerie, a granddaughter of Holocaust survivors and lifelong Jewish community leader, enrolled in Columbia's nonprofit management master's program in her 40s in 2022, only to witness a dramatic shift on campus after October 7th. She recounts facing anti-Jewish bias in the classroom even before the attacks, including a professor who chose Yom Kippur to assign anti-Israel readings when no Jewish students were present, and details how her complaints were ignored at every institutional level. Valerie ultimately became one of the named plaintiffs in a landmark civil rights lawsuit against Columbia, which recently resulted in a settlement. She discusses the personal cost of speaking up, from losing friends to needing a bodyguard, and the wins secured through the case: scholarships for students who've lived or studied in Israel, adoption of the IHRA definition of antisemitism, and the appointment of a Title VI coordinator. A powerful conversation about standing proud, showing up for the next generation, and refusing to be silenced. Guest: Valerie Gerstein Consider DONATING to help us continue and expand our media efforts. If you cannot at this time, please share this video with someone who might benefit from it. We thank you for your support!https://gofund.me/30c00151c BUY MERCH!https://hereiam.threadless.com/ SUPPORT SHAI ON PATREON!https://www.patreon.com/shaidavidai/about?utm_source=campaign-search-results

250 Year Competition:Vote for which of Trump's insiders you think the Founding Fathers would send back to Englandhttps://forms.gle/XFwsfqkec7UEsKxbAJames and Al discuss the DSA's wins in New York's primaries, the growing schism in the Democratic Party, the need to unite to win in the general, and the prevailing political narratives heading into the midterms, as well as the leaks weakening the Trump administration.  Then, they welcome pollster Jim Gerstein to examine our tumultuous relationship with Israel after the deal with Iran, the challenges facing Netanyahu, and who the country will look to after him.  They also examine the issues that will dominate the midterms and emphasize the need to focus on affordability and make gains with rural voters.Email your questions to James and Al at politicswarroom@gmail.com or tweet them to @politicon.  Make sure to include your city– we love to hear where you're from! More from James and Al:Get text updates from Politics War Room and Politicon.Watch Politics War Room & James Carville Explains on YouTube.James Carville & Al Hunt have launched the Politics War Room SubstackGet updates and some great behind-the-scenes content from the documentary CARVILLE: WINNING IS EVERYTHING, STUPID by following James on X @jamescarville and his new TikTok @realjamescarvilleGet More From This Week's Guest: Jim Gerstein: GBAO Strategies Please Support Our Sponsors:Miracle Made:Upgrade your sleep with Miracle Made! Go to TryMiracle.com/warroom and use the code WARROOM to claim your FREE 3-PIECE TOWEL SET and SAVE over 40% OFF.Smalls:Get 60% off your first order, plus free shipping and free treats for life, when you head to Smalls.com/WARROOMSuperpower:Head to Superpower.com and use code WARROOM at checkout for $20 off your membership. Unlock your new health intelligence. 100+ biomarkers. Every year. Detect early signs of 1,000+ conditions. #superpowerpodHers W.L.:Ready to reach your weight loss goals? Visit forhers.com/warroom to get personalized, affordable care that gets you.

Anthropic is voiding secondary market trades. Who gets hurt — WhatsApp scammers, Forge buyers, or the founders? Plus: why continuous synthetic pricing is coming for every pre-IPO company. Thank you to our sponsors!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Multichain Advisors: Get help navigating TGEs, go‑to‑market, BD and partnerships, capital markets advisory, PR, media placements, KOL activations and more at multichainadv.com. Coinbase: Get 20% off the first year of your Coinbase One annual plan at coinbase.com/unchained. Anthropic and OpenAI are moving to void secondary market trades — and Kain, Tay, and Luca think that's only going to work if they're serious about it, which means a lawsuit is probably coming. This week on Uneasy Money they trace the full anatomy of the pre-IPO SPV fraud wave, explain why synthetic perpetual markets will eventually price every in-demand private company continuously whether founders want it or not, and dig into the latest AI hacks. Tay breaks down how attackers are now using local on-device Gemini APIs to construct malware on the fly, and Kain shares the story of an agent that caught a slow-drain attack in 90 seconds that humans missed for 12 hours. Luca explains why Circle's Arc token is a brilliant move for Circle equity holders even if it changes nothing for ETH or Solana. Plus: the Aave/Kelp court update and why the Gerstein lawyers' argument that every victim needs to show up in court is fundamentally incompatible with how onchain recovery works. Hosts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Kain Warwick⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Founder of Infinex and Synthetix ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Taylor Monahan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Security Expert ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Luca Netz⁠⁠⁠⁠, CEO of Pudgy Penguins Learn more about your ad choices. Visit megaphone.fm/adchoices

Anthropic is voiding secondary market trades. Who gets hurt — WhatsApp scammers, Forge buyers, or the founders? Plus: why continuous synthetic pricing is coming for every pre-IPO company. Thank you to our sponsors!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Multichain Advisors: Get help navigating TGEs, go‑to‑market, BD and partnerships, capital markets advisory, PR, media placements, KOL activations and more at multichainadv.com. Coinbase: Get 20% off the first year of your Coinbase One annual plan at coinbase.com/unchained. Anthropic and OpenAI are moving to void secondary market trades — and Kain, Tay, and Luca think that's only going to work if they're serious about it, which means a lawsuit is probably coming. This week on Uneasy Money they trace the full anatomy of the pre-IPO SPV fraud wave, explain why synthetic perpetual markets will eventually price every in-demand private company continuously whether founders want it or not, and dig into the latest AI hacks. Tay breaks down how attackers are now using local on-device Gemini APIs to construct malware on the fly, and Kain shares the story of an agent that caught a slow-drain attack in 90 seconds that humans missed for 12 hours. Luca explains why Circle's Arc token is a brilliant move for Circle equity holders even if it changes nothing for ETH or Solana. Plus: the Aave/Kelp court update and why the Gerstein lawyers' argument that every victim needs to show up in court is fundamentally incompatible with how onchain recovery works. Hosts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Kain Warwick⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Founder of Infinex and Synthetix ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Taylor Monahan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Security Expert ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Luca Netz⁠⁠⁠⁠, CEO of Pudgy Penguins Learn more about your ad choices. Visit megaphone.fm/adchoices

As Emerging Technology continues to accelerate across domains like Artificial Intelligence (AI), Biotechnology, & Brain-computer interfaces coverage, humanity may be approaching a threshold that fundamentally redefines what it means to wage war – and what it means to be human.In this episode, host Dr. Arun Seraphin is joined by Dr. Daniel Gerstein, adjunct professor at American University and George Mason University, to discuss Dr. Gerstein's upcoming novel, War Without Humanity: Conflict in the Post-Human Era. Drawing on his extensive background in National Security and Homeland Security, Dr. Gerstein explores a near-future world in which humans, augmented soldiers, and AI-enabled humanoid robots operate side by side on the battlefield – a force he calls the Future Force.The conversation covers the Emerging Technology capabilities at the heart of this transformation and what these developments in Artificial Intelligence (AI) and Biotechnology mean for ethical military doctrine, arms control, and international law in an evolving National Security landscape.Be sure to follow us on social media for updates, early access to upcoming events, inside scoops, & more:LinkedIn: https://bit.ly/4htROo0Twitter: https://bit.ly/48LHAx3Facebook: https://bit.ly/47vlht8 And for more podcasts, articles, & publications all things emerging tech, check out our website at: https://bit.ly/47oA5K1 #EmergingTech #AI #BioTechnology #FutureForceKeywords:-            Emerging Technology-            Artificial Intelligence (AI)-            Biotechnology-            National Security-            Homeland Security-            Future Force

James and Al sound off on voting rights and review recent polling before welcoming Ed Luce of the Financial Times.  They discuss the future of Ukraine and the status of the war, the changing political landscape in the UK, and the growing US platform of King Charles and the Pope.  Then, they are joined by pollster Jim Gerstein to review current voter priorities, changing attitudes towards Israel and Netanyahu, the emerging Democratic candidates, the danger of MAGA election interference, and the possibility of a Blue Wave heading into the midterm elections.Email your questions to James and Al at politicswarroom@gmail.com or tweet them to @politicon.  Make sure to include your city– we love to hear where you're from! More from James and Al:Get text updates from Politics War Room and Politicon.Watch Politics War Room & James Carville Explains on YouTube.James Carville & Al Hunt have launched the Politics War Room SubstackGet updates and some great behind-the-scenes content from the documentary CARVILLE: WINNING IS EVERYTHING, STUPID by following James on X @jamescarville and his new TikTok @realjamescarvilleGet More From This Week's Guests: Ed Luce: Financial Times | Twitter | Author of “Zbig" & Many Other BooksJim Gerstein: GBAO Strategies Please Support Our Sponsor:Superpower:Head to Superpower.com and use code WARROOM at checkout for $20 off your membership. Unlock your new health intelligence. 100+ biomarkers. Every year. Detect early signs of 1,000+ conditions. #superpowerpod

SummaryIn this conversation, Patricia Morency discusses key aspects of autism, including its criteria, the nature of autism as a disability, and the importance of understanding the experiences of Black autistic individuals. She debunks common myths, particularly the misconception that vaccines cause autism, and highlights the lack of intersectionality in autism research and diagnosis. The conversation also addresses the racial bias present in autism diagnosis and treatment, emphasizing the need for more inclusive research practices.Resources: @blackspectrumscholar Linktree: https://linktr.ee/lapestenoire Chapters00:00 Understanding Autism: Criteria and Characteristics05:13 The Nature of Autism as a Disability08:31 Debunking Myths: Vaccines and Autism10:36 The Underrepresentation of Black Autistic Individuals18:16 Intersectionality in Autism Research and Diagnosis22:43 Racial Bias in Autism Diagnosis and TreatmentReferencesBaumgaertner Nunn, E., & Ghorayshi, A. (2025, September 25). What to know about painkillers, vaccines, genes, and autism. New York Times. https://www.nytimes.com/2025/09/22/health/autism-tylenol-vaccines-explained.htmlDiemer, M. C., Gerstein, E. D., & Regester, A. (2022). Autism presentation in female and Black populations: Examining the roles of identity, theory, and systemic inequalities. Autism: The International Journal of Research and Practice, 26(8), 1931–1946. https://doi.org/10.1177/13623613221113501Henderson, D., Wayland, S., & White, J. (2023). Is this autism? A guide for clinicians and everyone else. Routledge. https://doi.org/10.4324/9781003242130Ramclam, A. N., Truong, D. M., Mire, S. S., Smoots, K. D., McNeel, M. M., Sakyi, G. J., & Daniels, F. M. (2022). Autism disparities for Black children: Acknowledging and addressing the problem through culturally responsive and socially just assessment practices. Psychology in the Schools, 59, 1445–1453. https://doi.org/10.1002/pits.22646Wiesner, M., Windle, M., Kanouse, D. E., Elliott, M. N., & Schuster, M. A. (2015). DISC predictive scales (DPS): Factor structure and uniform differential item functioning across gender and three racial/ethnic groups for ADHD, conduct disorder, and oppositional defiant disorder symptoms. Psychological assessment, 27(4), 1324–1336. https://doi.org/10.1037/pas0000101

This is Part Two of our conversation.Montana's frontier history left behind more than old buildings and fading legends—some believe it left behind spirits that never moved on.For the team at Chilling Paranormal, exploring haunted locations isn't just about searching for evidence. It's also about protecting the history tied to those places. Led by Addison Gerstein, the Montana-based group hosts paranormal investigations that give people the opportunity to experience historic sites while helping support their preservation.Today, Addison takes us inside two of Montana's most infamous locations: the Old Montana State Prison and the Dumas Brothel.The prison operated from 1871 to 1979, witnessing riots, brutal conditions, and decades of inmate violence. Today, investigators report shadow figures, unexplained footsteps, and chilling EVP recordings echoing through the empty cell blocks.We also explore the Dumas Brothel, the longest continuously operating brothel in the United States. Built during Butte's mining boom and partially constructed underground, investigators say the building still carries a powerful energy tied to its complicated past.Sometimes history leaves behind more than stories.For more information, go to their website, chillingparanormal.com, find them on Facebook, TikTok, or Instagram.#TheGraveTalks #ParanormalPodcast #HauntedPrison #OldMontanaStatePrison #DumasBrothel #MontanaGhosts #HauntedHistory #GhostInvestigation #ChillingParanormal #ParanormalInvestigation #HauntedAmerica #ButteMontanaLove real ghost stories? Want even more?Become a supporter and unlock exclusive extras, ad-free episodes, and advanced access:

Montana's frontier history left behind more than old buildings and fading legends—some believe it left behind spirits that never moved on.For the team at Chilling Paranormal, exploring haunted locations isn't just about searching for evidence. It's also about protecting the history tied to those places. Led by Addison Gerstein, the Montana-based group hosts paranormal investigations that give people the opportunity to experience historic sites while helping support their preservation.Today, Addison takes us inside two of Montana's most infamous locations: the Old Montana State Prison and the Dumas Brothel.The prison operated from 1871 to 1979, witnessing riots, brutal conditions, and decades of inmate violence. Today, investigators report shadow figures, unexplained footsteps, and chilling EVP recordings echoing through the empty cell blocks.We also explore the Dumas Brothel, the longest continuously operating brothel in the United States. Built during Butte's mining boom and partially constructed underground, investigators say the building still carries a powerful energy tied to its complicated past.Sometimes history leaves behind more than stories.For more information, go to their website, chillingparanormal.com, find them on Facebook, TikTok, or Instagram. #TheGraveTalks #ParanormalPodcast #HauntedPrison #OldMontanaStatePrison #DumasBrothel #MontanaGhosts #HauntedHistory #GhostInvestigation #ChillingParanormal #ParanormalInvestigation #HauntedAmerica #ButteMontana Love real ghost stories? Want even more?Become a supporter and unlock exclusive extras, ad-free episodes, and advanced access:

“Everyone who might believe you can substitute robots for soldiers on the battlefield needs to read this book.” — General Wesley K. Clark, U.S. Army (Ret.), Former Supreme Allied Commander, EuropeIn this gripping episode of I Am Refocused Radio, we sit down with national security expert Dr. Daniel M. Gerstein to explore his powerful new book, War Without Humanity: Conflict in the Post-Human Era.The story opens in February 2039 on the tense Latvia–Russia border, where a U.S. Army platoon relies on humanoid robotic forces to hold the line—until the machines suddenly disobey orders and launch a cross-border attack. Connected through a brain–computer interface, the platoon leader watches in real time, unable to stop what could ignite World War III.From that chilling moment, the conversation expands into a real-world exploration of the technologies already reshaping modern warfare.We dive into the rise of augmented soldiers, artificial intelligence with human-level decision making, biotechnology that creates enhanced warfighters, and the Internet of Things turning the battlefield into a living network. As humans become nodes in a digital combat ecosystem, the line between man and machine begins to disappear.But the deeper questions go beyond strategy and innovation:When autonomous systems act on their own, who is accountable?If enhanced humans begin to see themselves as a new species, what happens to loyalty and command?Can humanity maintain its moral and spiritual identity in a post-human military age?Dr. Gerstein walks us through the evolution of a transhuman future force—from concept and testing to the road to war—revealing how today's research is shaping tomorrow's reality.This episode is not just about the future of combat.It's about leadership, responsibility, identity, and whether human values can survive in an era where evolution is no longer natural—but engineered.Get the book: https://a.co/d/0eVNlBqS

Recorded October 31, 2025 In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Kate Neville, immunologist turned seasoned biotech patent attorney at Marshall, Gerstein & Borun, to unpack one of the most misunderstood and mission-critical areas of life sciences: intellectual property.If you are a biotech founder, scientist, executive, or investor, this conversation is essential listening.We explore what patent prosecution really means, when startups should begin thinking about IP protection, how “freedom to operate” can determine commercial viability, and how emerging AI tools are reshaping the patent landscape.Dr. Neville brings 25+ years of experience guiding university spin-outs, biotech startups, and global pharmaceutical companies through complex patent strategy. She has helped secure patents for FDA-approved drugs and offers a rare dual perspective as both scientist and attorney.In This Episode We Discuss:• The difference between patent prosecution and patent litigation• Why it is never too early for biotech startups to think about IP• The U.S. one-year grace period vs. Europe's stricter disclosure rules• What “Freedom to Operate” really means for commercialization• Antibody patents, CDR regions, and the doctrine of equivalents• How premature disclosure can impact global patent strategy• The real-world back-and-forth of patent office “office actions”• AI-assisted prior art search at the USPTO — opportunity or risk?• How funding cycles influence patent filing decisions• Women in biotech leadership and venture funding disparities• The most rewarding part of protecting life-changing therapiesWe also break down the USPTO's new AI pilot programs designed to modernize patent examination and discuss how artificial intelligence may impact biotech patenting over the next several years.Why This MattersIntellectual property is often the single most valuable asset in a biotech company.Strong IP strategy can unlock funding, partnerships, and market exclusivity.Weak or mistimed IP decisions can permanently limit global opportunity.For founders and scientists: timing, geography, and disclosure discipline matter more than most people realize.About Our GuestDr. Kate NevillePartner, Marshall, Gerstein & BorunPhD in Immunology, JDLinkedIn: https://www.linkedin.com/in/kate-neville-phd/Firm Bio: https://www.marshallip.com/katherine-l-neville-ph-d/Charity Highlight: Girls on the Run ChicagoAn organization building confidence and resilience in young girls through mentorship and athletic achievement.https://www.girlsontherun.org/HostsDr. Chad BriscoeBioanalytical Scientific Leaderhttps://www.linkedin.com/in/chadbriscoe/Gregory AustinDirector, Business Development | Bioanalysishttps://www.linkedin.com/in/gregoryaustin1/If you enjoyed this episode, subscribe to BioTalk Unzipped on Apple Podcasts, Spotify, or your preferred platform and share with a colleague in biotech, pharma, or life sciences innovation.

Canellakis & Gerstein by CSO Association

On Tuesday's Mark Levin Show, WMAL's Larry O'Connor fills in for Mark. The media and radical left have not learned their lesson they're in the middle as they keep attacking President Trump instead of addressing that what occurred in Minnesota was wrong. The moment you say something about Somalians, you ae considered to be racist. Which is absolutely ridiculous. What the Somali community did regarding this money fraud scandal is sad, wrong, and evil. Also, Politico's Josh Gerstein suggested on X that knocking on doors at Minnesota daycare centers could “intersect” with stand-your-ground laws—think about that for a second. A journalist implying homeowners might legally shoot other journalists for investigating fraud? Outrageous! Independent reporter Nick Shirley exposed what looks like massive taxpayer-funded fraud, and instead of focusing on corruption, Gerstein warns about gun laws. Social media lit him up, and rightly so—he even got Minnesota law wrong, claiming “not in your home” when it's a duty-to-retreat state. This is the media protecting the establishment, intimidating citizen journalists, and proving once again why trust in these elitists is in the gutter.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

After a big win, James and Al explain why the Democrats outperformed in the off-season elections, focusing on the declining affordability of life under Trump, his anti-democratic actions, and the desire for change in the electorate.  Then, they look at the implications for the upcoming national elections, the growing headwinds to MAGA and Republican rule, and the potential to increase the share of the Hispanic vote.  They also examine the impact of statewide court decisions, the effects of redistricting following California's Proposition 50, and the state of international relations, with a focus on Israel. Email your questions to James and Al at politicswarroom@gmail.com or tweet them to @politicon.  Make sure to include your city– we love to hear where you're from! More from James and Al: Get text updates from Politics War Room and Politicon. Watch Politics War Room & James Carville Explains on YouTube @PoliticsWarRoomOfficial James Carville & Al Hunt have launched the Politics War Room Substack Get updates and some great behind-the-scenes content from the documentary CARVILLE: WINNING IS EVERYTHING, STUPID by following James on X @jamescarville and his new TikTok @realjamescarville Check Out Andrew Zucker's New Politicon Podcast: The Golden Age Get More From This Week's Guest:  Jim Gerstein: GBAO Strategies  Please Support Our Sponsors: Naked Wines: To get 6 bottles of wine for $39.99, head to nakedwines.com/warroom and use code WARROOM for both the code and password.  Green Chef: Get 50% off your 1st month, then 20% off for 2 months with free shipping when you use code 50WARROOM at greenchef.com/50warroom

Want to know how to cut it as an Editor?Benji Gerstein takes a break from his busy schedule to tell us all about his job - including his award-winning work on the smash-hit Netflix show, ‘Baby Reindeer'.As well as talking us through his process and sharing his advice for newcomers, Benji also gives us the inside story of his big night at the Emmys!FOLLOW US!Instagraminstagram.com/openingcreditsTikToktiktok.com/@weareopeningcreditsYouTubeyoutube.com/@weareopeningcredits Hosted on Acast. See acast.com/privacy for more information.

What are the implications of recent court decisions for artificial intelligence systems trained on copyrighted materials?In this episode I get to speak with two repeat veteran guests of the podcast about two important cases dealing with fair use analysis in the context of large language model training. Here are a couple of highlights: • Courts found AI training to be "transformative use" because the process changes the works significantly through tokenization and processing.• Judges distinguished between legally obtained training data (dismissed claims) and pirated training data (allowed claims to proceed).• Both judges signaled that if plaintiffs had focused on AI outputs reproducing substantial portions of their works, outcomes might have been different.• The transformative nature of AI training was deemed significant enough to qualify as fair use even for commercial enterprises• One judge noted that if copyrighted works are essential for training models worth "billions, if not trillions," developers must find ways to compensate copyright holders.About Our GuestsRyan Phelan and Tiffany Gehrke are recognized thought leaders in emerging technology law and artificial intelligence. Both are partners at Marshall, Gerstein & Borun LLP and returning guests on the Emerging Litigation Podcast.Ryan has written extensively on digital innovation, including intellectual property issues related to cutting-edge AI systems. He is the moderator of PatentNext, a blog focused on patent and IP law for next-generation technologies. We based our discussion on his excellent article about copyright law meeting AI, titled U.S. District Court Issues First Decisions on AI Model Development and Copyright Fair Use. Ryan holds a J.D. from Northwestern Pritzker School of Law and an MBA from Northwestern's Kellogg School of Management.Tiffany is known for her expertise in intellectual property and technology policy, and for advocating balanced, ethical approaches to AI regulation. She chairs Marshall Gerstein's Trademarks and Copyrights Practice. Before entering law, she worked as a software engineer. Tiffany earned her J.D. from Loyola University Chicago School of Law.Together, they bring deep practical insight and academic rigor to the evolving legal landscape surrounding artificial intelligence. I appreciate them returning to the podcast and sharing what they know!Tom HagyHostEmerging Litigation Pocast

In this episode of The New Chemist's Podcasting Group's — The Path to KOLs, host David Ferguson sits down with Christine Hollis, Chief Talent & Diversity Officer at Marshall Gerstein. Christine has dedicated her career to guiding scientists and engineers into impactful roles within intellectual property law, bridging the worlds of innovation and legal protection.She shares insights on:Pathways for STEM talent to enter IP law as patent agents or technical specialists.The skills scientists bring to legal environments and innovation ecosystems.Strategies for diversity, equity, and inclusion in science-driven law.The future of STEM-law collaboration in an era of AI, biotech, and medtech.Whether you're a student, scientist, or innovator, Christine's vision will broaden your perspective on how STEM expertise can shape industries beyond the lab.Disclaimer: These episodes do not constitute medical or professional advice. These are only for intellectual engagement. Please see your local and board-certified health professional for medical advice, consultation, and suggestions.Music by Viacheslav Starostin from Pixabay

Daniel M. Gerstein, senior policy researcher at RAND and former acting under secretary at the DHS Science and Technology Directorate, joins Steve Gruber to break down President Trump's recent executive orders on drone policy. He outlines what the new directives mean for national security, privacy, and the rapidly evolving role of unmanned systems in both domestic and global contexts.

Ryan Phelan is a partner and patent attorney at Marshall Gerstein. He discusses his journey from a background in computer science and fintech to becoming a prominent IP attorney serving clients in the MedTech industry and beyond. He shares insights on the importance of protecting intellectual property, especially for startups, and the burgeoning role of AI in medical technology. This succinct yet fascinating conversation highlights the critical intersection of law, technology, and medical innovation. Guest links: https://www.marshallip.com | https://www.patentnext.com/  Charity supported: Sleep in Heavenly Peace Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editing: Marketing Wise Producer: Velentium   EPISODE TRANSCRIPT Episode 058 - Ryan Phelan [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and I am so looking forward to my conversation today with Ryan Phelan. Ryan is a partner and patent attorney at the Chicago based intellectual property law firm, Marshall Gerstein, where he counsels medtech companies on protecting their valuable IP. Ryan ultimately believes that AI is an important technology to embrace, but cautions medical device and related companies to approach it pragmatically, developing a policy to govern and protect intangible assets and innovation. All right. Well, thank you so much for being here, Ryan. I'm so excited to speak with you today. [00:01:29] Ryan Phelan: Yeah. Thank you for having me. Thank you, Lindsey. [00:01:31] Lindsey Dinneen: Of course. Well, I'd love if you'd start off by sharing a little bit about your background and what led you to medtech. [00:01:39] Ryan Phelan: Sure, absolutely. So I'm an attorney by trade. And I started off in probably a different place than most people in MedTech, but I have a computer science degree and I worked in industry first for Accenture, doing a lot of programming and consulting in the FinTech world. So, high frequency trading and programming some pretty complicated data algorithms in order to trade stocks and bonds and securities, and things like this. That let me see aspects of intellectual property that people were doing with respect to the code I was writing. So I got curious with IP and law, and that led me to law school, Northwestern Law, in pursuing a joint JD, MBA program, which I finished in 2010. And I went into IP law with a passion for technology, pretty much in the computing space. And then in the last decade or so, IP practitioners, not unlike doctors, like to practice in specific areas and one of the ones that I focused on is software medical devices. And so that, that kind of led me into the realm of medtech. [00:02:48] Lindsey Dinneen: Very nice. Okay. So you have had such an interesting career trajectory and I'm wondering, back in the day, say you're a six year old Ryan, could six year old Ryan have predicted that you would be a lawyer and particularly intellectual property? [00:03:04] Ryan Phelan: Absolutely not. I mean, first of all nobody in my family, at least immediate family, was a lawyer. And so going to law school was not on the radar. I grew up in Louisiana in a small town, basically farm life, so certainly technology and stuff like that wasn't available in the city. But I did have a passion for things that were tech. I was certainly a kid that loved to take things apart and put them back together and build all kinds of Legos and stuff like that. So that basic kind of STEM acumen or desire was always there from the beginning. And so, as I, I grew up and got exposed to more things, certainly in college, it became kind of a passion. And so, I ended up doing that. We did have some medical issues in my family, including cardiac and cancer and stuff like that. So, those types of things always hit home with me and you're getting to a chance to kind of lean into medtech, at least on the software side, with medtech devices that include or incorporate medical technology became very interesting to me personally. [00:04:07] Lindsey Dinneen: Yeah, of course. And so going back just a smidgen when you decided to go into law and you know, you've come from this background that was the software engineering and you've got this fintech background and you have all of these amazing skill sets already, what led you specifically to say, "Okay, I want to focus on intellectual property, and so this is going to be my, my sweet spot." [00:04:33] Ryan Phelan: Yeah. So when you go to law school, you get exposed to a lot of different classes. In fact, in your first year law school, you're required to take a bunch of baseline courses like criminal law and all these things. And so you quickly figure out what you like and what you don't like. And so for me, a computer science degree is always kind of the beating heart of what I loved. And so I wanted to, I tended to like, classes that were up that alley, so to speak. And the IP course that I took was definitely there because it was all about technology, inventions, people making things, and how those inventions played out in court. So I found my greatest joy in law school to be in those classes. So I spoke up the most in class and did the best. There's common saying that "you should do things that you love because you never have to work a day in your life" kind of thing. So I always try to think about that, and certainly fun today because I practice in IP and picked that direction. [00:05:27] Lindsey Dinneen: Yeah, absolutely. So, in addition to all of the other credentials you have, you are also a published author and you are a speaker. And I would love if you would share maybe a little bit more about how you got into being a thought leader as well in your industry and how that path has taken you. [00:05:51] Ryan Phelan: Yeah, for sure. It's the same kind of thing. I've always liked to write as well. And I feel that when I write about something, I really get to understand it. And so in my field, there's a lot of stuff happening all the time. Like a court will come out with a new case, an IP and medtech or AI or something like this, and I really like to dig into it to figure out how can I use this court decision as a tool for clients, or how does this change things up? What will clients ask me questions going forward, or how can this be an interesting topic to either write about or to speak about? And so, I try to learn when I'm reading, and then I write it, and that teaches me, and I think and hope that others get a benefit from that too when I publish, so. [00:06:34] Lindsey Dinneen: Yes, of course. Of course. And you are also, if I'm not mistaken, an adjunct professor. So, first of all, do you sleep? And second of all, tell me more about this as well, please. [00:06:47] Ryan Phelan: Yeah, so I'm an adjunct professor at Northwestern Law. I teach a course on patenting software inventions. I do sleep because it's only once a year for a power week. You know, I think it's like three days out of the year. There's the long classes, they're like a few hours each, but we pack in several 30 minute core sessions into a day. So one day, maybe we'll go for three hours or two hours. And, you know, we will get the benefit of several weeks of coursework by doing all of that at once in those three days. And so, I teach on that. We teach fundamentals of patenting softwares and inventions, which includes medtech software devices. For example, the FDA classifies software, medical inventions in, in, in certain ways, like their software as a medical device where you have the software only such as, you have database with medical data and you're either formatting it or storing it or processing in some unique way, or you have software in a medical device where you actually have a physical device. It's a cardiac device where the software is running or at least partially running that device. And so we talk about ways to, to patent those inventions primarily with US law. So. [00:07:59] Lindsey Dinneen: Very nice. So specifically thinking about your medtech clients, because I know you probably have clients in many industries, but specifically in medtech, what are some of the common mistakes you see medtech companies making? Especially say, you know, an earlier startup or something like that, when maybe they haven't thought through an aspect that really should be thought through a little bit earlier in the process. What are some common things that you see that people should be aware of? [00:08:27] Ryan Phelan: Yeah, I mean, easily one of them is not filing a patent application early. And if they are a startup company and they have their biggest selling product, or what they think will be their biggest selling product, and they don't file a patent application on it, that could be bad because you have one year to get to the patent office with that, at least in the U. S. to file something once it's been publicly disclosed. And if you miss that deadline, then effectively you're allowing your competitors to copy it. And if you're a startup company, the last thing you want is for your product to become extremely successful and then a big Fortune 500 company gets wind of it, figures out you don't have a patent, and then just starts making it themselves and it takes away your market share. So that would be, you know, I think that's every inventor of startups like worst nightmare, right? So, getting that patent on file before the deadline is pretty important. [00:09:22] Lindsey Dinneen: Yeah, of course. Now, I noticed you had recently written an article on LinkedIn about when to file this patent. And I know part of maybe some concerns that might arise are, "Well, we don't necessarily want this to be in public awareness yet." So how do you walk that line between "This is our IP, we're really trying to keep it very tight," versus, "But I also need this protection, this legal protection." So how do you navigate things like that? [00:09:54] Ryan Phelan: Yeah, so the point at which you need to make your invention publicly available or to disclose it because you need to, you know, maybe you're going to pitch competition and you need to show your invention on like a PowerPoint deck in front of hundreds of people. Then that's probably a good point to start thinking about filing a patent application if you're still developing it, and it's like in your basement, so to speak, and nobody's seen it. It's still secret then. You don't need to necessarily file a patent application at that point. Although, there's a funny thing in patent law where, if you have an idea, sometimes there's somebody else thinking about it too, and the first one to get the patent office, wins, and so, you certainly don't want to wait around too long and find out years later that you filed your patent application the day after somebody else. This actually happened with Thomas Edison and the light bulb and he had lots of fights about the other person that was claiming the same thing that lost, and we don't remember his name today because of that. So anyway, so that's one thing to keep in mind when you're starting out. [00:10:54] Lindsey Dinneen: Yeah. Well, and speaking of those kinds of stories, are there any that particularly stand out to you as you've worked with all of these incredible clients who have seriously life changing products they're creating. Are there any that really stand out to you in your memory as affirming, "Oh my goodness, this is why I'm here. This is why I'm doing what I'm doing." [00:11:17] Ryan Phelan: Yeah, for sure. One that stands out is one in the opioid or the narcotics market. In my family, we have an individual who is unfortunately affected by this. And so, I had a client that reached out to me to create a VR program that helps to eliminate or to reduce cravings in this field. And that one was really impactful because using technology and non pharmaceutical way in order to reduce cravings for people that are struggling with addiction of some type, I felt to be very important. So I thoroughly enjoyed working with that inventor and helping to, to create that patent application for that invention. [00:11:59] Lindsey Dinneen: Yeah, of course. Yeah. Thank you for sharing about that. I think sometimes those really personal connection kinds of stories are the ones that really stick in your mind because it, it helps to have this moment of realization, like you know that what you do matters, of course, but then having that extra layer of confirmation that "Yes, this is helping somebody who could literally be a family member or a close friend or relative" is really impactful. [00:12:25] Ryan Phelan: Exactly. [00:12:26] Lindsey Dinneen: Yeah. So considering all of the industries that you currently serve, and of course, you have this incredibly varied background, which can only be wonderful to draw on from this rich history and experience of yours. What are some interesting crossovers you see between industries that can be useful in terms of, maybe one industry approaches something in a way that you've seen could actually really benefit folks in medtech or vice versa. Are you seeing trends like that? [00:12:59] Ryan Phelan: Yeah, absolutely. I mean, one of the biggest ones that I can think of now is artificial intelligence coming into play with medtech. I mean, certainly, medtech kind of runs the gamut of, you know, like, like we mentioned before software only to physical devices that incorporate software. And so AI is interesting because you can load it and AI model onto one of these physical devices, or you can have an AI model that's medtech based sitting on a server somewhere that can help doctors look or find particular cause or whatnot like that, based on symptoms that a patient may walk into, or maybe there's a device, like a needle, that allows that has an AI model on it that helps with injection or something like this. And so, these AI tools are becoming smarter. And I think that they help in the field of medtech and they require a different level of expertise with these inventions to not only create them because they're complex, but also to bring them to market because they require specific FDA regulations. Even the FDA right now is trying to figure out AI. They have approved several AI devices, but it usually comes down to, you know, is your AI device going to change in the near future because you're going to update the model? And if so, does that change it enough to require like a new submission? So the fact that AI moves so rapidly doesn't really mix well with the FDA's process of approving the device and having it set in stone at that approval state. [00:14:30] Lindsey Dinneen: Yeah. So where do you anticipate that this will take medical devices? Do you think it'll become so naturally ingrained in many of them that it's just sort of part of our reality, or do you think we'll still have those --what do we want to call them-- not AI functionality devices? [00:14:48] Ryan Phelan: Yeah, I think both will exist. You know, certainly a spectrum of these devices, right? Certainly there's surgical tools that exist now that have hundreds of years, or a hundred years, just in different, maybe better forms. So, those will stay, stick around. The AI assisted ones, I'm sure will find their niche, and live alongside the the existing tools. [00:15:10] Lindsey Dinneen: Yeah, absolutely. If you could narrow it down, what would be maybe your top piece of advice for a MedTech startup founder from your perspective, in your role? [00:15:23] Ryan Phelan: Yeah, I guess the number one would be again to, you know, make sure you're not giving away your crown jewels. Have your patent filed before you step out. If you're trying to raise money, just be careful that you're not sharing information publicly. You have to share with a potential investor, consider an NDA or if they won't sign an NDA, you can file a provisional patent application with the patent office. That shows that you have something on file before you talk to others. And as long as you describe the invention sufficiently in the four corners of your provisional application, then that's often the best way to protect yourself going out. So I think, as an IP attorney, that, that would be the number one advice that I would give a startup company in the medtech space. [00:16:10] Lindsey Dinneen: That's incredible. Thank you for that. That's really appreciated advice. So, it's so interesting because when I was looking at your LinkedIn profile, of course you have all of this incredible experience, and one thing actually really stood out to me, and that was that at least at some point you have been a and --I'm sure you've done this throughout your career multiple times-- but a pro bono lawyer for Lawyers for the Creative Arts. And I was curious about that and how you got involved, and can you share a little bit about that journey? [00:16:40] Ryan Phelan: Yeah. So LCA or Lawyers for the Creative Arts is an organization here in Chicago that deals with artists of limited means. You know, usually they have some type of basic issue that they want handled and it mainly deals with IP. Typically, I work on a different capacity for these because I see them as like kind of fun learning opportunities. I usually work in the copyright space and the clients that I work with need help either filing a copyright for maybe a piece of art that they've created, or maybe have a question about how their IP is being used or sold in some way, and they need to figure out if their IP has been infringed. And so, we'll work with them in a pro bono capacity to help write a letter to a company or to file a copyright registration and things like that. [00:17:28] Lindsey Dinneen: Well, as a, as my side thing as also an artist, I just want to say thank you because it is so great that you're doing things like that for the artist community. It is not always easy. So, oh, that's great, appreciate it. Yeah. So as you look towards your own future, what are you excited about say in the next year or two? [00:17:50] Ryan Phelan: Very excited to see how, I guess, AI is playing out with medtech. You're seeing regulations and guidelines coming out that The United States Patent and Trademark Office and also the Copyright Office about how these laws will impact artists. I've sat on a panel with the Copyright Office and the United States Patent and Trademark Office as they're thinking through these decisions and putting out these guidelines. There is questions about, is the new administration going to change things up with respect to guidance and guidelines that have come out. So, you know, artists are looking at AI is like a tool, like a paintbrush. And the law is kind of looking at it, obviously from the legal perspective and it doesn't seem like those two things are aligned yet. There's common in, in history that the law typically lags the technology by, you know, a decade or two or more. And so that's certainly the case with AI. For example, there is a famous -- I wouldn't call it a case-- but a denial of a copyright registration at the copyright office for a gentleman that had created an AI piece of artwork, won the Colorado state fair, I think in 2022, and tried to file a copyright registration, but was denied. And he told the copyright office, basically he had entered in 500 plus prompts in order to generate, or at least partially generate, this work of art, but was still denied . Not because of his effort, just because of the way the law is written under current copyright statutes. And so, things like that seem to be, at least from a policy perspective, incorrect. And so it'd be great to see exciting how this plays out. Will Congress care enough to change it or how will artists be impacted under these types of laws and policy considerations going forward? [00:19:35] Lindsey Dinneen: Yeah, absolutely. So pivoting the conversation a little bit just for fun, imagine that you were to be offered a million dollars masterclass on anything you want. It can be within your industry or part of your amazing background, or it could be about something entirely different. What would you choose to teach? [00:19:55] Ryan Phelan: Yeah. Wow. You know, I guess I would teach what I'm currently teaching. Cause I, I do enjoy the class I teach now. I'm at Northwestern, my alma mater, which I love. It's down the street from the office, get to go in same place where I went to school and teach the law and things that I do every day, which is patenting software inventions, including the medtech space. If I could get a million dollars to teach what I do now, that would be wonderful, in this hypothetical, so. [00:20:22] Lindsey Dinneen: Right. I love it. Excellent. And how do you wish to be remembered after you leave this world? [00:20:30] Ryan Phelan: Wow. I hope people remember me as someone who was fun loving and enjoyed tech and hopefully brought some information to the world that helped them in some way. [00:20:42] Lindsey Dinneen: Yeah, of course. And final question, what is one thing that makes you smile every time you see or think about it? [00:20:51] Ryan Phelan: Oh, wow. I guess there's a lot of stuff. I also like to do some type of sports. Currently, the ski season is ending, so I certainly enjoy skiing, so when I see or think about that's one of those things, and now coming is the golf season, so I transitioned into that. We're looking forward to some good weather here, finally, in Chicago. It was 80 degrees last week, and it snowed yesterday, so things are changing from golf to ski season, but one of those is always fun, so. [00:21:17] Lindsey Dinneen: That's awesome. That's fantastic. Yeah. If folks who are listening are in a position, would there be a way for them to get in contact with you and then how early should they do that actually? [00:21:31] Ryan Phelan: Yeah. There's multiple stages. They can get in touch with me anytime they want. You can always find me at our firm's website, Marshall Gerstein. Or if you want to, you can go to patentnext.com, just patent and the word next. com. That's my blog that I write on typically, and it has my contact information there, including my email address. [00:21:51] Lindsey Dinneen: Perfect. Well, thank you so much. Well, Ryan, it has been a joy to speak with you today. I really appreciate you sharing a little bit about your career and your insights, your advice, especially appreciate that for MedTech founders who might, you know, not quite know where to start with this whole legal element that they really need to consider. So I really appreciate you sharing kind of when and how to do that. And we're excited to be making a donation on your behalf, as a thank you for your time today, to Sleep in Heavenly Peace, which provides beds for children who don't have any in the United States. So thank you for choosing that charity to support. And thank you again so much for being here. This has been a wonderful conversation, and I just wish you the most continued success as you work to change lives for a better world. [00:22:41] Ryan Phelan: Thank you, Lindsey. My pleasure. Happy to be here too. Thank you for having me. [00:22:44] Lindsey Dinneen: Of course. And for our listeners, thank you so much for tuning in. If you're feeling as inspired as I am, I'd love it if you'd share this episode with a colleague or two, and we'll catch you next time. [00:22:56] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

How do you patent health tech inventions in today's challenging IP landscape, especially when AI is reshaping the game? We explore the complex world of patenting health technology inventions with Ryan Phelan, U.S. Patent Attorney and Partner at Marshall, Gerstein & Borun LLP. Health tech innovations, from AI-powered diagnostic tools to surgical robotics, often face unique patent hurdles. This is especially true under the U.S. Patent Office's evolving guidelines.  What you'll learn: Why many health tech patents get rejected as "organizing human activity" Proven strategies and workarounds to successfully patent healthcare IT and software-driven medical devices The explosive growth of AI patents in healthcare and what it means for innovators  Tips for healthcare startups and executives to protect their breakthroughs and intellectual property If you're working in healthcare innovation, med tech, medical device development, AI in health, or intellectual property law, this episode offers essential insights to help you safeguard your inventions. Find Ryan's work at: www.marshallip.com Subscribe and stay at the forefront of the digital healthcare revolution. Watch the full video on YouTube @TheDigitalHealthcareExperience The Digital Healthcare Experience is a hub to connect healthcare leaders and tech enthusiasts. Powered by Taylor Healthcare, this podcast is your gateway to the latest trends and breakthroughs in digital health. Learn more at taylor.com/digital-healthcare About Us: Taylor Healthcare empowers healthcare organizations to thrive in the digital world. Our technology streamlines critical workflows such as procedural & surgical informed consent with patented mobile signature capture, ransomware downtime mitigation, patient engagement and more. For more information, please visit imedhealth.com   The Digital Healthcare Experience Podcast: Powered by Taylor Healthcare Produced by Naomi Schwimmer  Hosted by Chris Civitarese Edited by Eli Banks Music by Nicholas Bach  

In Johannes Familie war Weinen kein großes Thema, über Gefühle reden auch nicht. Das hat sich auf seine Beziehungen ausgewirkt. Ein Experte erklärt, warum Männer oft keine Worte für ihre Gefühle finden und wie sie es – auch später noch – lernen können.**********Ihr hört: Gesprächspartner: Johannes, konnte früher keine Trauer spüren, hat besseren Zugang zu seinen Gefühlen gelernt Gesprächspartner: Jonas Rudolph, hat Soziale Arbeit und Psychologie studiert, promoviert zu Männlichkeit und Emotionen, wissenschaftlicher Mitarbeiter an der Internationalen Psychoanalytischen Universität in Berlin Gesprächspartner: Benjamin Wagner, systemischer Psychotherapeut, leitet mit einem Kollegen die Männergruppe "Mannsbuilder" in Wien Autor und Host: Przemek Żuk Redaktion: Yevgeniya Shcherbakova, Grit Eggerichs, Friederike Seeger Produktion: Dorothee Lohse, Philip Adelmann**********Quellen:Drogand-Strud, M. (2021). Lebenswelten/Männlichkeitsbilder von Jungen* und Männern*. In: Fobian, C., Ulfers, R. (Hrsg.) Jungen und Männer als Betroffene sexualisierter Gewalt. Sexuelle Gewalt und Pädagogik, 7. Springer VS, Wiesbaden.Connor S. et al. (2021). Perceptions and Interpretation of Contemporary Masculinities in Western Culture: A Systematic Review. American Journal of Men's Health, 15(6).Logoz, F. et al. (2023). How do traditional masculinity ideologies and emotional competence relate to aggression and physical domestic violence in cisgender men?. Frontiers in Psychology, 14.Cherry, K.E. & Gerstein, E.D. (2021). Fathering and masculine norms: Implications for the socialization of children's emotion regulation. Journal off Family Theory and Review, 13(2).Oliffe, J.L. et al. (2022). Masculinities and men's emotions in and after intimate partner relationships. Sociology of Health and Illness, 45(2).Alle Quellen findet ihr hier.**********Mehr zum Thema bei Deutschlandfunk Nova:Partnerschaft: Warum alle Beziehungen von weniger Romantik profitierenFeminismus: Was geht mich das als Mann an?Allyship: So werden Männer gute Verbündete für Frauen**********HörtippHier geht's zur Eine-Stunde-Liebe-Podcastfolge: "Partnerschaft: Warum alle Beziehungen von weniger Romantik profitieren"**********Den Artikel zum Stück findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .**********Meldet euch!Ihr könnt das Team von Facts & Feelings über Whatsapp erreichen.Uns interessiert: Was beschäftigt euch? Habt ihr ein Thema, über das wir unbedingt in der Sendung und im Podcast sprechen sollen?Schickt uns eine Sprachnachricht oder schreibt uns per 0160-91360852 oder an factsundfeelings@deutschlandradio.de.Wichtig: Wenn ihr diese Nummer speichert und uns eine Nachricht schickt, akzeptiert ihr unsere Regeln zum Datenschutz und bei Whatsapp die Datenschutzrichtlinien von Whatsapp.

Welcome to the Real Estate Finder Podcast as we are joined by Sandy T. Gerstein, an expert in professional organizing and moving logistics management. With a passion for helping clients move effortlessly and create harmonious living spaces, she founded STG Concierge Moving & Organizing to offer an all-in-one Concierge experience where every detail is meticulously planned and executed for you.Originally from New York and now based in sunny South Florida she earned degrees in Sociology and Business from Washington University, and holds a Masters in Education from Hunter College. Whether you are Buying or Selling, moving or just unpacking, Sandy can help you straighten out your life.Check her out at: www.stgconcierge.comWant to know more? Send us an email or ask to join us on The Real Estate Finder Podcast!www.RealEstateFinder.comShop podcast T-shirts: prowrestlingtees.com/matthewmaniaCheck out some of the best vendors and service providers in Florida:RealEstateFinder.com/PreferredVendorsSubscribe to our newsletter or see past issues at:RealEstateFinder.com/NewsletterBrought to you by: Matthew H. MaschlerReal Estate BrokerSignature Real Estate Finder, LLCwww.RealEstateFinder.comAsk about joining the Signature team! Learn more about the Signature Real Estate Companies and why you should join South Florida's real estate industry leaders, Ranked #1 in Boca Raton, #25 in Florida and #336 in the Nation.SignatureRecruiter.comOffices in Boca Raton, Delray Beach, Coral Springs / Parkland, Ft Lauderdale, Miami, Naples, Palm Beach, Orlando and throughout Florida.And be sure to check out BocaRatonWrestling.comLearn how to support our efforts to provide housing in Haitifrank-mckinney.com/caring-house-projectHelp Israel Now! All support goes Straight to Israel's Soldierswww.yasharlachayal.org

By Adam Turteltaub It's not a good time to be a manufacturer of ten-foot poles. That's because with the growing number of sanctions regimes, there are an increasing number of companies and individuals that businesses shouldn't touch with a poll of ten feet, or any length for that matter. Rachel Gerstein, who most recently served as Vice President, Global Ethics and Compliance Counsel for Gartner, explains in this podcast that trade sanctions are laws and regulations designed to prevent and punish engaging with countries, organization and individuals who the government has deemed a threat to national and international security, or has committed human rights violations. Many countries have sanctions regimes, although the United States tends to have the strongest. The US, for example, has countrywide sanctions against Iran, Cuba, Syria and North Korea, as well as numerous sanctions against Russian individuals and entities. The government's enforcement arm is the Department of the Treasury's Office of Foreign Assets Control (OFAC), which has developed comprehensive guidance for compliance programs. It includes five pillars that will sound very familiar to anyone in compliance: Management commitment Risk assessment Internal controls Testing and monitoring Training In addition to the obvious similarities in compliance program design, there is also great practical overlap. Third party vetting for anticorruption risk, for example, can also include sanctions-related checks. When determining if the company's owners are politically exposed, it's an ideal time to determine if there is 50% ownership by a sanctioned individual or entity. Training is another common element and particularly important. Individuals involved in payments and account receivable need to be educated in sanctions risks and what to watch out for. Employees across the workforce also need to be sensitized to the issue. Europeans, for example, may see Cuba as just another exotic Caribbean vacation destination and not realize the risk. Of course, there are also different tools also used for sanctions compliance. Your bank, for one, may be an asset given that it may be keeping its own list of sanctioned entities. Geoblockling is a tool that can be used to determine what country someone is communicating to you from and can be used by you to block interactions. In short, there is a great deal of risk, but there are great similarities with other compliance efforts, enabling you to combine sanctions compliance with other compliance efforts. But, you're still not likely to need that ten-foot pole. Listen now Sponsored by Case IQ, a global provider of whistleblowing, case management, and compliance solutions.

Canellakis & Gerstein - Broadcast by CSO Association

Daniel M. Gerstein is a senior policy researcher at RAND and a professor of policy analysis at Pardee RAND Graduate School. Previously, he served at the U.S. Department of Homeland Security (DHS) as under secretary (acting) and deputy under secretary in the Science & Technology Directorate. Emerging Technology and risk Assessment: The Space Domain and Critical Infrastructure

1056. Ghostwriting is more than just anonymous book writing — it's a thriving industry. Dan Gerstein, founder of Gotham Ghostwriters, shares how writers can break into ghostwriting, what types of projects are available, and how much top ghostwriters earn. Plus, we explore the ethical considerations of ghostwriting and how the industry is evolving.Dan Gerstein is founder and CEO of Gotham Ghostwriters, the country's premier ghostwriting agency. Featuring a network of more than 4,000 accomplished freelance editorial pros, Gotham specializes in sophisticated, long-form writing (such as books, speeches, and reports) for authors, speakers, and thinkers who need expert help telling and selling their stories. Gerstein, a graduate of Harvard College, has been writing and communicating professionally for more than 30 years. He started his career as a local sports and news reporter at the Hartford Courant. He then went on to spend more than a decade as a speechwriter and communications strategist on Capitol Hill and for two presidential campaigns, serving as a senior advisor to Senator Joe Lieberman from his home state of Connecticut.In 2004, Gerstein moved to New York to become a political consultant (primarily working with issue advocacy groups) and commentator. Known for his independent, thoughtful analysis, he has served as a contributing columnist for Forbes, the Wall Street Journal, and Politico. He has also appeared regularly on television as a political analyst for Fox News, CNN, MSNBC, WNBC-TV, and NY1.Among other pursuits, Gerstein, 57, has served as an adjunct faculty instructor in New York University's master's program in Public Relations and Corporate Communications; he currently serves on the board of the recently-launched 5Boro Institute in New York City. He lives in Manhattan with his wife Simona, their daughter Ella, and their dog Ugo.

In our latest episode, Roberto sits down with Noam Gerstein, CEO and founder of Bina, a global accredited virtual school pioneering precision education. Noam shares her visionary insights on online education, discussing the practicalities and wonders of teaching digitally, including the benefits of small class sizes, highly trained educators, real-time feedback, and a unique thematic approach to learning. Throughout the conversation, Noam elaborates on how Bina's innovative methods cater to young learners across diverse time zones and cultural contexts. She highlights the importance of social-emotional learning, cultural inclusivity, and maintaining student engagement through various interactive and collaborative strategies. Moreover, Noam provides a fascinating glimpse into the future of early childhood and elementary education, emphasizing the role of technology in creating more accessible, impactful, and personalized learning experiences. Welcome to Our Classroom!

In this episode, Zal Dastur interviews Ryan Shermahorn, a patent attorney and partner at Marshall, Gerstein & Borun, to explore the critical intersection of climate change, clean technology, and intellectual property. They dive into the Climate Change Mitigation Pilot Program, which accelerates the patent process for climate-focused innovations, highlighting how this program can benefit startups and smaller companies. Ryan explains why securing patents is essential for attracting investors, safeguarding innovations, and mitigating risks from patent trolls and counterfeiters. The conversation also unpacks the challenges of protecting AI-related patents, strategies for navigating international markets, and the often-overlooked resources available to clean tech innovators.

For more than 30 years Dr. Joseph Gerstein has been collecting stories from SMART participants about powerful emotional experiences related to their recovery journey. He has now written a captivating essay about the nature of these occurances that includes examples and analysis of what he calls "secular conversion experiences." His insight into the value of these experiences and the common elements found paints a picture of how our cognitive functions connect with the more emotive features of our lives. Dr. Gerstein is SMART's Founding President and a retired professor of medicine at Harvard Medical School. He has been instrumental in the growth of SMART in the U.S. and across the globe and has personally facilitated over 4,000 SMART meetings over 34 years. 

In this episode of Why Distance Learning?, hosts Seth Fleischauer, Allyson Mitchell, and Tami Moehring welcome Noam Gerstein, CEO of the Bina School and a leading expert in precision education. Noam shares her journey of creating a global, digitally native school that reimagines how education serves young learners, blending emotional connection, cultural diversity, and innovative uses of live virtual learning. The episode explores Bina School's unique approach to play-based, personalized learning for students aged 4 to 12, with a focus on fostering global awareness and nurturing emotionally safe, collaborative learning environments.Key Topics Discussed:The importance of emotionally held learning spaces in live virtual education.How Bina School uses thematic biomes and SDG projects to create meaningful learning experiences.The role of adaptive content generation in balancing personalization and standardization.Building a global community for young learners and redefining what a school can be.Guest Bio: Noam Gerstein is the CEO of the Bina School, a pioneer in precision education and a thought leader in the field. With a background in history, technology, and social innovation, Noam has spent years researching global education systems and building solutions to meet the needs of Gen Alpha learners. She is a frequent speaker at education conferences and a passionate advocate for blending cultural diversity with cutting-edge technology.Host Links:Discover more virtual learning opportunities and resources at CILC.org with Tami Moehring and Allyson Mitchell.Seth Fleischauer's Banyan Global Learning provides meaningful global learning experiences that prepare students across the globe for success in an interconnected world.Episode Links:Bina School - thebinaschool.comContact Noam Gerstein: noam@bina.school

Daniel M. Gerstein is a senior policy researcher at RAND and professor of policy analysis at Pardee RAND Graduate School. Previously, he served at the U.S. Department of Homeland Security (DHS) as under secretary (acting) and deputy under secretary in the Science & Technology Directorate. Security Threats Posed by Drones

Politics War Room ON TOUR  - live show in Boston on 11/2 at politicon.com/tour  Watch Politics War Room & James Carville Explains on YouTube @PoliticsWarRoomOfficial James and Al share their takes on the candidates' closing arguments, contextualize Biden's garbage comment, and examine the effect of Trump's MSG rally before welcoming pollsters Jim Gerstein and Dr. Whit Ayers. They discuss the numbers going into the final week of the election, explore the most significant issues influencing voters, debate how the undecided might break, compare what we see to recent elections, and weigh the chances Colin Allred has of defeating Ted Cruz in the race for the Texas Senate seat. Email your questions to James and Al at politicswarroom@gmail.com or tweet them to @politicon.  Make sure to include your city– we love to hear where you're from! More from James and Al Get tickets for the Politics War Room live shows in Boston on 11/2 at politicon.com/tour  Get text updates from Politics War Room and Politicon. Watch Politics War Room & James Carville Explains on YouTube @PoliticsWarRoomOfficial CARVILLE: WINNING IS EVERYTHING, STUPID hits theaters November 1st at the Angelika in D.C.  Get tickets now at CarvilleDoc.com/tickets.  You can also get updates and some great behind-the-scenes content by following James on Twitter @jamescarville and his new TikTok @realjamescarville James Carville & Al Hunt have launched the Politics War Room Substack Get More From This Week's Guests:  Jim Gerstein: GBAO Strategies  Dr. Whit Ayres: Twitter | University of Chicago | North Star Opinion | AAPC | Author Please Support Our Sponsors: HelloFresh: Get 10 free meals at hellofresh.com/freewarroom applied across 7 boxes– new subscribers only, varied by plan. Naked Wines: To get 6 bottles of wine for $39.99, head to nakedwines.com/warroom and use code WARROOM for both the code and password.   Laundry Sauce: For 15% off your order, head to laundrysauce.com/warroom and use code WARROOM

This week drive deeper into the history of the Dumas Brothel, as we're guided through it's haunted rooms ahead of our lock-in.  Learn more about Addison and Chilling Paranormal at https://www.chillingparanormal.com/  The full rebroadcast will be available at theFrightdaySociety.org soon...  Watch the video version at http://youtube.com/frightday Questions? Comments?  True Tales of Terror? Call the Frightday Hotline: 1(833)374-4489 1(833)FRI-GHT9 Pick up our limited edition August shirt at http://shop.frightday.com Want more? Join the Frightday Society, at http://thefrightdaysociety.org As a Society Member, you'll have access to all Screamium content (Behind the Screams, It's Been a Weird Week, A Conversation With..., Toast to Toast PM with Wine Kelly, Cinema Autopsy, the Writers' Room, bonus episodes of Captain Kelly's Cryptids & Conspiracies, Byron's Serial Corner, and so much more! You'll also be part of our interactive community dedicated to the advancement of horror, hauntings, cryptids, conspiracies, aliens, and true crime. All things frightening. Keep our mini-fridges full of blood...I mean...not blood...normal things that people drink...by going to http://shop.frightday.com  Theme music by Yawns Produced by Byron McKoy Follow us in the shadows at the following places: @byronmckoy @kellyfrightday @frightday  This is an Audio Wool Original.

Following Biden dropping out of the race, Al and James tear apart the GOP's reaction to Kamala's rise, rebuke their racism, and lay out JD Vance's attacks on Trump before welcoming seasoned pollster Jim Gerstein.  They discuss Kamala's strong opening bid and why the American people are happy to have a different choice. Then, they encourage her campaign to focus on the rising cost of living, reforming immigration, and protecting abortion rights.  They also react to Netanyahu's reception in Washington, explain his precarious political situation, and highlight the electoral issues with Trump's VP choice. Email your questions to James and Al at politicswarroom@gmail.com or tweet them to @politicon.  Make sure to include your city– we love to hear where you're from! Watch James Carville Explains on YouTube Playlist James Carville & Al Hunt have launched the Politics War Room Substack Get More From Jim Gerstein  GBAO Strategies  Please Support Our Sponsor: Miracle Made: For 40% off high-quality self-cooling sheets, plus an extra 20% off with 3 free towels, use promo code WARROOM when you go to TryMiracle.com/warroom

In this episode of the 3DPOD, we take a deep dive into IP, patents, and more with Meggan Duffy, Partner at Marshall Gerstein. As an entrepreneur our co-host Max is especially engaged in this episode. It was very practical, offering a lot of actionable learnings on IP. The takeaway for me was that in our business, you need an IP strategy and must be very engaged with this subject. Chock full of practical information, this is a great episode to learn more about IP.

Kirill Gerstein's new album, timed for release mid-way between the anniversary of the death of Claude Debussy (March 25) and Armenian Genocide Remembrance Day (April 24), pairs music by Debussy and the Armenian, Komitas. Both composers were profoundly affected by the death and destruction surrounding them during the First World War, and both responded with music of multi-layered intensity. Gerstein links late Debussy piano music with Komitas's piano works, as well as songs by each composer. 'Music in the Time of War' is released to stream and download by Platoon, and on two CDs with a substantial book of essays next month by Myrios. James Jolly spoke to Kirill Gerstein to learn about the project and why he brought together these two powerful musical voices in the same programme. This Gramophone Podcast is produced in association with Wigmore Hall.

In the shadows of corporate greed and exploitation lies a sinister crime that is silently perpetrated, leaving countless victims in its wake—a crime that affects millions of hardworking Americans every year and sucks billions out of our economy —Wage Theft. No industry is immune to this insidious crime, from restaurant workers to construction laborers. On this episode of Pitchfork Economics, we are joined by Terri Gerstein, Director of the Labor Initiative at NYU Robert F. Wagner Graduate School of Public Service, to unpack the chilling truth behind these workplace crimes, learn who the perpetrators are, and uncover how they get away with it. Most importantly, what can be done to stop them? Terri Gerstein is the Director of the NYU Wagner Labor Initiative, at NYU's Robert F. Wagner Graduate School of Public Service, which explores and helps activate the often-untapped potential of government in safeguarding and advancing workers' rights. Previously, Terri enforced labor laws in New York for 17 years, including as Labor Bureau Chief in the New York State Attorney General's Office. Crime music bed by Power Music Factory News clips from CBS News, CBS Miami, and CBS Philadelphia Twitter: @TerriGerstein  NYU Wagner Labor Initiative Further reading:  Prosecute Bad Bosses: More district attorneys are cracking down on abusive employers. It's about time Report mentioned in the episode from the National Coalition Against Insurance Fraud: The Costly Crime and Impact of Workers' Comp Premium Fraud The Role of State Attorneys General in Protecting Workers' Rights Report: How district attorneys and state attorneys general are fighting workplace abuses More states should follow new Colorado policy on wage theft Website: http://pitchforkeconomics.com Twitter: @PitchforkEcon Instagram: @pitchforkeconomics Nick's twitter: @NickHanauer

Daniel (Dan) M. Gerstein is a senior policy researcher at the RAND Corporation. Previously, he served at the U.S. Department of Homeland Security (DHS) as under secretary (acting) and deputy under secretary in the Science & Technology Directorate.   Emerging Technology and Risk Analysis: Artificial Intelligence (AI) and Critical Infrastructure

Daniel M. Gerstein, board member of the Pandemic Mitigation Project, formerly served as the acting undersecretary and deputy undersecretary in the Department of Homeland Security's Science and Technology Directorate from 2011 to 2014. Hidden in Plain Sight: the Next Biosecurity Threat

In this episode, Made for Impact host Gretchen Schott and guest Mara Gerstein discuss the importance of self-awareness and self-exploration in personal and professional growth. Mara, Co-Founder and CEO of Loupe Ventures, a self-awareness tool that turns feedback into actionable data and insights takes us through the power of a growth mindset, how to take your leadership skills to the next level through feedback, and developing a high-performing culture. Additional Resources: Connect with Gretchen Schott on LinkedIn  Connect with Mara Gerstein on LinkedIn  Original Episode Made for Impact Podcast Call for a Feedback Revolution Loupe Ventures Website More on PeopleForward Network Follow PeopleForward Network on LinkedIn  

James and Al skewer so-called family values Republicans after recent scandals and welcome polling experts Fred Yang and Jim Gerstein.  They dive into the weak numbers being put up by the Biden campaign, analyzing what's bringing them down, the composition of the electorate, the role of 3rd party candidates, the messaging challenges ahead, and how to take the lead.  They cover the effects of inflation, the crisis at the border, the lack of enthusiasm among young and minority voters, the Israel-Hamas war, and whether Dobbs has given Democrats a silver bullet.  Plus with the year kicking off, James and Al tackle the latest in college sports as long time fans. Email your questions to James and Al at politicswarroom@gmail.com or tweet them to @politicon.  Make sure to include your city, we love to hear where you're from! Check James Carville's new videos: James Carville Explains… Moms For Liberty #TrumpStinks James Carville Explains… Why Mike Johnson is a P.O.S. James Carville Explains… everything about Mike Johnson James Carville on the trail of Lauren Boebert Get More From This Week's Guests: Jim Gerstein  GBAO Strategies  Fred Yang: Twitter | Hart Research  Please Support Our Sponsors: Henson Shaving: Go to hensonshaving.com/pwr and enter PWR at checkout to get 100 free blades with your purchase. (Note: you must add both the 100-blade pack and the razor for the discount to apply.) Zbiotics: Get back into action with Zbiotics with 15% off your first order of the perfect solution to a night out when you go to zbiotics.com/pwr and use code: PWR

What is Asset Framing? We talk with Anat Gerstein, Founder and President, on a new push to help properly and respectfully report on at-risk and marginalized populations. Anat started her namesake named firm in 2010 after years of seeing first-hand the support nonprofits need to effectively tell their story. Prior to starting her business, Anat was chief of staff and press secretary to NYC Public Advocate Betsy Gotbaum; provided public relations services to top healthcare companies, including Eli Lilly and Cigna; developed effective communications materials for social service and other non-profits; and promoted political candidates at the state and local level. She began her career nearly 25 years ago in the advertising sector, working on consumer brands such as Vicks and Crest. Anat is a graduate of New York University's Stern School of Business and a Sabra (Israeli native). Anat served on The New York Community Trust Nonprofit Excellence Awards Selection Committee from 2013 to 2018. The PR Podcast is your view inside the public relations business. We talk with great PR people, reporters, and communicators about how the news gets made and strategies for publicity that drive business goals.  Host ⁠⁠Jody Fisher⁠⁠ is the founder of JodyFisherPR and works with clients across the healthcare, higher education, financial services, real estate, entertainment, and non-profit verticals.  Join the conversation on ⁠⁠Facebook⁠⁠, ⁠⁠Twitter⁠⁠, ⁠⁠Instagram⁠⁠, and ⁠⁠TikTok⁠⁠ at @ThePRPodcast. --- Support this podcast: https://podcasters.spotify.com/pod/show/theprpodcast/support

"Understanding ourselves is a never-ending journey, and feedback from others can be a valuable compass that guides us towards our true potential." Mara Gerstein is the Co-Founder and CEO of Loupe Ventures, a self-awareness tool that turns feedback into actionable data and insights. She has a passion for innovation and has played a pivotal role in nurturing and empowering emerging tech companies. In this episode of Made For Impact, Mara discusses the power of a growth mindset, how to take your leadership skills to the next level through feedback, and developing a high-performing culture.  In this episode, you'll learn:  The importance of self-awareness and self-exploration in personal and professional growth. The challenges and limitations of traditional performance management systems and how they can be improved. Strategies and tools for creating a positive feedback culture in organizations that foster growth, engagement, and productivity.   Connect with GUEST: https://www.linkedin.com/in/mara-gerstein-ba74a014/ Check out Loupe Ventures: www.AskLoupe.com   Get in touch with Gretchen, and let her know which impactful leaders you'd like to hear from: Connect on LinkedIn or Subscribe to our newsletter.   Loved this episode? Leave us a review and rating here: https://link.chtbl.com/3EbmWF5a   

Following the tragic attack on Israel by Hamas, James and Al are joined by political strategist Jim Gerstein to break down the situation on the ground and its regional ramifications.  They delve into the potential for a wider conflict, how a follow-up invasion can destroy the prospects for Middle East peace, and how the Israeli government is responding.  Then, they welcome Brigadier General Ty Seidule to examine the tactics used and the harm to our military readiness caused by Republicans.  Between their war on the diversity of our troops and Senator Tuberville's blockade of military promotions, are we ready for the next crisis?    Email your questions to James and Al at politicswarroom@gmail.com or tweet them to @politicon.  Make sure to include your city, we love to hear where you're from! Get More From This Week's Guests: Jim Gerstein  GBAO Strategies  Brigadier General Ty Seidule (Ret.): Twitter | West Point | Website | Hamilton College | New America | Author of “Robert E. Lee & Me” Please Support This Week's Sponsors: Lomi: Turn your food waste into plant-food at the press of a button with Lomi. Use the code WARROOM to save $50 at lomi.com/WARROOM Zbiotics: Get back into action with Zbiotics with 15% off your first order of the perfect solution to a night out when you go to zbiotics.com/pwr and use code: PWR Miracle Made: For 40% off high quality self-cooling sheets plus an extra 20% off with 3 free towels with promo code WARROOM, go to trymiracle.com/warroom

Canna-tourism generated $17B+ last year, and a wave of state legalization means that number will only get higher.  Brooke is the owner of Green Bonnet Pharms in Oklahoma, a complete vertically integrated cannabis business from seed to smoke, and she takes us through the challenges and opportunities in a travel sector primed for growth (and green).https://www.greenbonnetco.com/https://www.instagram.com/greenbonnetpharms/https://www.budandbreakfast.com/https://www.instagram.com/campcana/

Daniel M. Gerstein works at RAND and is an adjunct professor at American University. He formerly served as the undersecretary (acting) and deputy undersecretary in the Science and Technology Directorate of the Department of Homeland Security from 2011 to 2014. Healthy nation, safe nation: Build health security into national security

This week on the podcast I am joined by Nancy Gerstein. Nancy is a yoga and meditation teacher, author, and the founder of Motivational Yoga, a practice that helps empower and clarify one's life decisions, goals, and results. Her classes feed body and mind, encouraging students to make conscious choices about how they direct thoughts, energy, and focus to live the best life they can. In this episode, Nancy and I dive into discussing how to plan and promote a workshop both in-person and online. Nancy shares her top tips for deciding your workshop idea, planning for your workshop, marketing your workshop, and then executing and delivering. Enjoy! *This episode originally aired in June 2021

Daily News Brief for Wednesday May 4th, 2022 Plug Do you have a podcast, or are you thinking about starting one? Does your church have a podcast feed for sermons? The Dropwave.io is for you. Cancel culture is like walking on a thin glass bridge over the Grand Canyon. Every step you take could get you killed, I mean canceled. Since the beginning CrossPolitic has been working on being antifragile, so no matter what happens, our content can still be delivered to your tv and to your podcast. This past year, the Waterboy and his friend Jeremi, have been working on building a podcast hosting solution for rowdy platforms like CrossPolitic, so that you can be confident your podcast will never fall through that glass bridge. Dropwave offers seamless onboarding for shows that have been around for years to easy to use solutions for starting your own podcast. Dropwave will track all your show’s downloads by city, state, and country, and it offers network and enterprise packages for solutions like the Fight Laugh Feast Network. Free to speak, Free to podcast, free to start your journey now at www.Dropwave.io. Supreme Court has voted to overturn abortion rights, draft opinion shows https://www.politico.com/news/2022/05/02/supreme-court-abortion-draft-opinion-00029473 As you are aware by now, Politico released a leaked “The Supreme Court has voted to strike down the landmark Roe v. Wade decision, according to an initial draft majority opinion written by Justice Samuel Alito circulated inside the court and obtained by POLITICO. The draft opinion is a full-throated, unflinching repudiation of the 1973 decision which guaranteed federal constitutional protections of abortion rights and a subsequent 1992 decision — Planned Parenthood v. Casey — that largely maintained the right. “Roe was egregiously wrong from the start,” Alito writes. “We hold that Roe and Casey must be overruled,” he writes in the document, labeled as the “Opinion of the Court.” “It is time to heed the Constitution and return the issue of abortion to the people’s elected representatives.” Deliberations on controversial cases have in the past been fluid. Justices can and sometimes do change their votes as draft opinions circulate and major decisions can be subject to multiple drafts and vote-trading, sometimes until just days before a decision is unveiled. The court’s holding will not be final until it is published, likely in the next two months. The immediate impact of the ruling as drafted in February would be to end a half-century guarantee of federal constitutional protection of abortion rights and allow each state to decide whether to restrict or ban abortion. It’s unclear if there have been subsequent changes to the draft.” Was the Constitution silent on abortion and does tradition make room for abortion being legal? More from Politico on this: “The inescapable conclusion is that a right to abortion is not deeply rooted in the Nation’s history and traditions,” Alito writes. Much of Alito’s draft is devoted to arguing that widespread criminalization of abortion during the 19th and early 20th century belies the notion that a right to abortion is implied in the Constitution. The conservative justice attached to his draft a 31-page appendix listing laws passed to criminalize abortion during that period. Alito claims “an unbroken tradition of prohibiting abortion on pain of criminal punishment…from the earliest days of the common law until 1973.” “Until the latter part of the 20th century, there was no support in American law for a constitutional right to obtain an abortion. Zero. None. No state constitutional provision had recognized such a right,” Alito adds. Alito who wrote the majority opinion in this draft, according to Politico, had a number of sharp things to say: “At times, Alito’s draft opinion takes an almost mocking tone as it skewers the majority opinion in Roe, written by Justice Harry Blackmun, a Richard Nixon appointee who died in 1999. “Roe expressed the ‘feel[ing]’ that the Fourteenth Amendment was the provision that did the work, but its message seemed to be that the abortion right could be found somewhere in the Constitution and that specifying its exact location was not of paramount importance,” Alito writes. Alito declares that one of the central tenets of Roe, the “viability” distinction between fetuses not capable of living outside the womb and those which can, “makes no sense.” “The Constitution does not prohibit the citizens of each State from regulating or prohibiting abortion,” the draft concludes. “Roe and Casey arrogated that authority. We now overrule those decisions and return that authority to the people and their elected representatives.” Here is my two cents on this: First, leaks happen for a reason, and this leak is egregious intentional. The abortion culture will do anything to keep their blood sacrifice, and that is the whole point of this leak. Secondly, since the leak was intentional, here are the chess pieces they are trying to influence. Option 1: Get one (or two, we dont know) Justices to change their position in the next two months. Option 2: If one of the Justices get suicided before the vote is finalized, then the decision will go in favor of the blood sacrifice crowd. Option 3: Try and get everyone to rally in the November elections, and stave off a Republican wave…sort of the COVID effect. Create chaos, which democrats just love, just look at their cities, and steal the election in November. Third thing to consider here. Chief Justice John Roberts has ordered an investigation into the leak, so this letter is probably pretty accurate with the direction the ruling was/is going, and the word on the street was that it was Amit Jain clerks for Supreme Court Justice Sonia Sotomayor leaked the draft (https://twitter.com/MattWolking/status/1521303528421171203?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1521303528421171203%7Ctwgr%5E%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fwww.lifenews.com%2F2022%2F05%2F03%2Fif-justice-sonia-sotomayor-was-involved-in-supreme-court-leak-she-should-be-impeached%2F). Matt Woking, Republican advisor and strategist, connected some dots on Twitter last night and said that “As a Yale student, Jain blasted Yale for supporting Brett Kavanaugh's nomination. Jain was quoted in a 2017 Politico piece by Josh Gerstein. Today, Gerstein published the draft SCOTUS opinion on Roe.” If this leak came from Sotomayor’s office, she should be impeached after November, and replaced by a Republican House and Senate. Well here is Biden’s Statement on this leak and draft decision: COVID Science has wrecked our industrial medical complex. No one trusts their “science” anymore and so guys like Dr. Jay and others are working hard to be trusted voices in the midst of all this confusion. Dr. Martin Kulldorf, Epidemiologist, Biostatistician, and Former Harvard Professor of Medicine released the “Twelve Forgotten Principles of Public Health”, and they are: #1 Public health is about all health outcomes, not just a single disease like #COVID19. It is important to also consider harms from public health measures. #2 Public health is about the long term rather than the short term. Spring #COVID19 #lockdowns simply delayed and postponed the pandemic to the fall. #3 Public health is about everyone. It should not be used to shift the burden of disease from the affluent to the less affluent, as the #COVID19 #lockdowns have done. #4 Public health is global. Public health scientists need to consider the global impact of their recommendations. #5 Risks and harms cannot be completely eliminated, but they can be reduced. Elimination and zero-COVID strategies backfire, making things worse. #6 Public health should focus on high-risk populations. For #COVID19, many standard public health measures were never used to protect high-risk older people, leading to unnecessary deaths. #7 While contact tracing and isolation is critically important for some infectious diseases, it is futile and counterproductive for common infections such as influenza and #COVID19. #8 A case is only a case if a person is sick. Mass testing asymptomatic individuals is harmful to public health. #9 Public health is about trust. To gain the trust of the public, public health officials and the media must be honest and trust the public. Shaming and fear should never be used in a pandemic. #10 Public health scientists and officials must be honest with what is not known. For example, epidemic models should be run with the whole range of plausible input parameters. #11 In public health, open civilized debate is profoundly critical. Censoring, silencing and smearing leads to fear of speaking, herd thinking and distrust. #12 It is important for public health scientists and officials to listen to the public, who are living the public health consequences. This pandemic has proved that many non-epidemiologists understand public health better than some epidemiologists. / END New study: Face mask usage correlates with higher death rates https://www.israelnationalnews.com/news/326734 According to Israel National News: A new peer-reviewed study entitled: "Correlation Between Mask Compliance and COVID-19 Outcomes in Europe" has demonstrated that use of face masks, even widespread, did not correlate with better outcomes during the COVID epidemic, based on data from 35 European countries with populations of over one million people each, encompassing a total of 602 million people. The study noted that the average proportion of mask usage in the period investigated (October 2020 until March 2021) was 60.9% ± 19.9%. Governments and advisory bodies have recommended and often mandated the wearing of face masks in public spaces and in many areas mandates or recommendations remain in place, despite the fact, the study notes, that randomized controlled trials from prior to and during the epidemic have failed to show a benefit to the wearing of such masks with regard to COVID transmission. "Positive correlation between mask usage and cases was not statistically significant," the study also found, "while the correlation between mask usage and deaths was positive and significant (rho = 0.351, p = 0.039)." That is to say, more mask usage correlated with a higher death rate. The study used a variety of statistical methods to study correlation but "none of these tests provided negative correlations between mask usage and cases/deaths ... Surprisingly, weak positive correlations were observed when mask compliance was plotted against morbidity (cases/million) or mortality (deaths/million) in each country." The study also noted that the public may have gained the impression that masks could be helpful due to the fact that mandates were usually implemented after the first peak of COVID cases had passed. However, it became evident that masks were not in fact helpful later that same year, when widespread mask usage does not appear to have mitigated the severity of the COVID wave of winter 2020. "Moreover," the study concludes, "the moderate positive correlation between mask usage and deaths in Western Europe also suggests that the universal use of masks may have had harmful unintended consequences." Elon Musk goes scorched-earth on NBC after Peacock host's attack, notes network's worst scandals https://www.foxnews.com/media/elon-musk-scorched-earth-nbc-peacock-host-insults-notes-networks-worst-scandals?intcmp=fb_fnc According to Fox News: Tesla CEO Elon Musk took a scorched-earth approach to NBC on Monday after a left-wing Peacock host accused him of handing Twitter "to the far-right." "NBC basically saying Republicans are Nazis …" Musk wrote in a Monday tweet, responding to a video clip posted by another user showing Mehdi Hasan railing against Musk, calling him a "not-so-bright billionaire," and complaining about his purchase of the social media giant. "Same org that covered up Hunter Biden laptop story, had Harvey Weinstein story early & killed it & built Matt Lauer his rape office. Lovely people," Musk added in another tweet, listing some of the network's most notorious scandals in recent years. This is Gabriel Rench with Crosspolitic News. Support Rowdy Christian media by joining our club at fightlaughfeast.com, downloading our App, and head to our annual Fight Laugh Feast Events. If this content is helpful to you, would you please consider becoming a Fight Laugh Feast Club Member? We are trying to build a cancel-proof media platform, and we need your help. Join today and get a discount at the Fight Laugh Feast conference in Knoxville, TN and have a great day. Have a great day. Lord bless